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missense mutations. Retrospective assessment of 260 de novo glioblastoma (GBM)
patients revealed a significant reduction in overall survival of patients with EGFR
mutations at alanine 289 (EGFRA289D/T/V). Quantitative multi-parametric MRI
analyses indicated increased tumor invasion for EGFRA289D/T/V mutants, a finding
corroborated in mice bearing intracranial tumors expressing EGFRA289V and
dependent on ERK-mediated expression of matrix metalloproteinase-1 (MMP1).
EGFRA289V tumor growth was attenuated with an EGFRvIII conformation-specific
antibody based on a hypothesized structural convergence. Collectively, the findings of
this study indicate a highly invasive and prognostic indicator for the EGFRA289V
missense mutation in GBM, postulating EGFRA289V as a molecular marker for
responsiveness to therapy with EGFR-targeting antibodies.
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Cancer Cell 
Editor-in-Chief 
Dr. Li-Kuo Su 
50 Hampshire St., 5th Floor 
Cambridge, MA 02139 
 
Dear Dr. Su: 
 
Thank you for the opportunity to address the reviewers’ concerns and questions. We feel that in 
doing so, we have strengthened the conclusions of the manuscript. A point-by-point explanation 
for the comments has been included. Of note, the latter half of Reviewer #2’s comments 
addressed the radiomics portion of the manuscript. Those responses and edits, in combination 
with our response to Reviewer #1’s second comment, have significantly strengthened the 
contributions of the radiomics to our work. Moreover, in response to the concerns raised by 
Reviewer #1, we believe these responses have validated the inclusion of the imaging data in the 
current manuscript. 
 
We have also included two validation cohorts to address Reviewer #2’s 1st and 2nd comments.  
The French cohort, from Hôpital Pitié-Salpêtrière, was obtained prior to 2009, so it fulfills the 
external requirement but is dated.  The UPenn validation cohort was obtained from 2015-2017, 
so it is contemporary and a distinct cohort, but from our own institution.  We feel the inclusion of 
these two cohorts both fully addresses the Reviewer’s comments and strengthens the 
conclusions drawn. 
 
There are no financial conflicts of interest or competing interests to report with this submitted 
manuscript. The work described has not been previously published or currently submitted 
elsewhere for your review. The targetability of glioblastoma missense mutations by mAb806 
shown in our manuscript is now supported by a bioRxiv reference (DOI: 10.1101/009068) as the 
Cancer Cell submission, Orellana et al., CANCER-CELL-D-16-00999, is still under arbitration. 
Since this manuscript provided the structural basis for the therapeutic use of mAb806 against 
EGFR missense mutations, and here we demonstrate the feasibility of this approach in vivo, 
both manuscripts do not overlap in any way but are complementary pieces. We want to reaffirm 
that our manuscript and Orellana et al are completely separate and independent manuscripts. 
Thank you in advance for considering this submission, we hope you will find our work consistent 
with the aim and scope of Cancer Cell. 
 
If we can provide any further information, please do not hesitate to contact us. We look forward 
to hearing from you soon. 
 
Sincerely, 
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Donald M. O’Rourke, M.D 
Associate Professor 
Department of Neurosurgery 
Abramson Cancer Center 
Perelman School of Medicine 
University of Pennsylvania 
Philadelphia, PA 19104 
donald.orourke@uphs.upenn.edu 
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Reviewer's comments: 
Reviewer #1: The authors examine the EGFR extracellular domain missense mutation at alanine 289 
(EGFRA289D/T/V). They find that these mutations promote tumor invasion via ERK-mediated MMP1 
expression. EGFRA289V tumor growth was attenuated with an EGFRvIII conformation-specific antibody. 
The authors may wish to consider the following points 
 
1. The impact of this work would be enhanced if the authors could show that tumors that were 
responsive to ABT-414 in clinical trials were enriched to have the EGFR-A289 mutations. The section 
entitled " mAb806 is a potential therapeutic option for patients.." is perhaps optimistic in that patient 
data are not included. Given that there are patients who have been treated with ABT-414, testing 
whether the A289 mutation is predictive of response would be impactful 
 
We agree with Reviewer #1 in that investigating the survival of EGFR A289 mutant patients on the 
ABT-414 trial would be very impactful. Unfortunately, the logistics involved in that sub-population 
analysis are prohibitive. Specifically, in the ABT-414 Stage IIb/III clinical trial, of the anticipated ~700 
patients enrolled, approximately 35 patients will have an A289 mutation, based on a 5% occurrence 
rate. As the trial is randomized, we presume <20 patients with an A289 mutation will be receiving 
ABT-414. Additionally, the majority of enrolling locations do not sequence their tumors, so the 
identification of A289 mutant patients in the trial will be difficult, if not impossible. As an example, 
the University of Pennsylvania has enrolled 5 patients, of which none have had the mutation. Given 
the difficulty in identifying all of the mutant patients on the trial, we feel that running a sub-
population analysis in the current trial is not feasible. Importantly, the clinical trial enrollment 
recently closed and the data have not been made available for review at this stage. We do, however, 
hope the conclusions in this manuscript will help inform future EGFR-targeting trials to include a sub-
population analysis of the EGFR A289 mutant population. 
 
 
2. The radiomics data lacks validation and is somewhat distracting, and takes away from the main 
message of the manuscript. 
 
We appreciate the concerns raised by Reviewer #1 regarding the radiomics data. However, we feel 
that including the radiomics data is useful for ascertaining our underlying hypothesis and reasoning 
behind focusing on the further assessment and analysis of the A289 mutation. We also believe that 
the radiomics data offers an insight on imaging differences that are not apparent to standard MRI 
interpretation, only after advanced computational analysis. In order to better justify the use of the 
radiomics data and demonstrate their validity in various studies, we have included additional 
citations from the literature, both from our group and others (see below). In these studies, 
computational analysis of radiomics data has been shown to be predictive of clinical outcome and 
molecular characteristics. In addition, we have softened the language in the discussion associated 
with radiomics, emphasizing that we used the imaging findings in a hypothesis-generating manner, 
not a hypothesis-driven manner, on page 11. The additional references cited in the manuscript are as 
follows, with papers from our group listed in bold, followed by other citations that, due to length 
limitations on the paper, not all of them have been included: 
Response to Reviewers
• H.J.Aerts. “The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review” JAMA 
Oncol. 2016 Dec 1;2(12):1636-1642. doi: 10.1001/jamaoncol.2016.2631. 
• S.Bakas, H.Akbari, J.Pisapia, M.Martinez-Lage, M.Rozycki, S.Rathore, N.Dahmane, 
D.M.O’Rourke, C.Davatzikos. "In vivo detection of EGFRvIII in glioblastoma via perfusion 
magnetic resonance imaging signature consistent with deep peritumoral infiltration: the φ 
index", Clin Cancer Research, 23(16):4724-4734, August 15 2017. DOI: 10.1158/1078-0432.CCR-
16-1871 
• S.Bakas, Z.A.Binder, H.Akbari, M.Martinez-Lage, M.Rozycki, J.J.D.Morrissette, N.Dahmane, 
D.M.O’Rourke, C.Davatzikos. "Highly-expressed wild-type EGFR and EGFRvIII mutant 
glioblastomas have similar MRI signature, consistent with deep peritumoral infiltration." 
Neuro Oncol. 18:vi125-vi126, 2016 DOI: 10.1093/neuonc/now212.523 
• B.M.Ellingson, E.R.Gerstner, M.Smits, R.Y.Huang, R.Colen, L.E.Abrey, D.T.Aftab, G.M.Schwab, 
C.Hessel, R.J.Harris, A.Chakhoyan, R.Gahrmann, W.B.Pope, K.Leu, C.Raymond, D.C.Woodworth, 
J.de Groot, P.Y.Wen, T.T.Batchelor, M.J.van den Bent, T.F.Cloughesy. “Diffusion MRI Phenotypes 
Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: 
Converging Evidence from Phase II Trials” Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. DOI: 
10.1158/1078-0432.CCR-16-2844 
• O.Gevaert, S.Echegaray, A.Khuong, C.D.Hoang, J.B.Shrager, K.C.Jensen, G.J.Berry, H.H.Guo, 
C.Lau, S.K.Plevritis, D.L.Rubin, S.Napel, A.N.Leung. “Predictive radiogenomics modeling of EGFR 
mutation status in lung cancer” Sci Rep. 2017; 7: 41674. DOI: 10.1038/srep41674 
• B.J.Gill, D.J.Pisapia, H.R.Malone, H.Goldstein, L.Lei, A.Sonabend, J.Yun, J.Samanamud, J.S.Sims, 
M.Banu, A.Dovas, A.F.Teich, S.A.Sheth, G.M.McKhann, M.B.Sisti, J.N.Bruce, P.A.Sims, P.Canoll. 
“MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition 
at the margins of glioblastoma”. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12550-5. DOI: 
10.1073/pnas.1405839111 
• D.A.Gutman, L.A.D.Cooper, S.N.Hwang, C.A.Holder, J.Gao, T.D.Aurora, W.D.Dunn Jr, L.Scarpace, 
T.Mikkelsen, R.Jain, M.Wintermark, M.Jilwan, P.Raghavan, E.Huang, R.J.Clifford, P.Mongkolwat, 
V.Kleper, J.Freymann, J.Kirby, P.O.Zinn, C.S.Moreno, C.Jaffe, R.Colen, D.L.Rubin, J.Saltz, 
A.Flanders, D.J.Brat. “MR imaging predictors of molecular profile and survival: multi-institutional 
study of the TCGA glioblastoma data set” Radiology. 2013 May; 267(2): 560–569 DOI:  
10.1148/radiol.13120118 
• H.Itakura, A.S.Achrol, L.A.Mitchell, J.J.Loya, T.Liu, E.M.Westbroek, A.H.Feroze, S.Rodriguez, 
S.Echegaray, T.D.Azad, K.W.Yeom, S.Napel, D.L.Rubin, S.D.Chang, G.R.Harsh, O.Gevaert. 
“Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct 
molecular pathway activities” Sci Transl Med. 2015 Sep 2;7(303):303ra138. DOI: 
10.1126/scitranslmed.aaa7582 
• L.Macyszyn, H.Akbari, J.M.Pisapia, X.Da, M.Attiah, V.Pigrish, Y.Bi, S.Pal, R.V.Davuluri, 
L.Roccograndi, N.Dahmane, M.Martinez-Lage, G.Biros, R.L.Wolf, M.Bilello, D.M.O'Rourke, 
C.Davatzikos. “Imaging patterns predict patient survival and molecular subtype in 
glioblastoma via machine learning techniques”, Neuro Oncol. 2016 Mar; 18(3): 417–425. DOI:  
10.1093/neuonc/nov127 
 
Additional references not included in the manuscript (due to space limitations) 
• H.Akbari, L.Macyszyn, X.Da, M.Bilello, R.L.Wolf, M.Martinez-Lage, G.Biros, M.Alonso-Basanta, 
D.M.O'Rourke, C.Davatzikos. “Imaging Surrogates of Infiltration Obtained Via 
Multiparametric Imaging Pattern Analysis Predict Subsequent Location of Recurrence of 
Glioblastoma”, Neurosurgery. 2016 Apr;78(4):572-80. doi: 10.1227/NEU.0000000000001202 
• K.Chang, H.X.Bai, H.Zhou, C.Su, W.L.Bi, E.Agbodza, V.K.Kavouridis, J.T.Senders, A.Boaro, 
A.L.Beers, B.Zhang, A.Capellini, W.Liao, Q.Shen, X.Li, B.Xiao, J.Cryan, S.Ramkissoon, 
L.Ramkissoon, K.L.Ligon, P.Y.Wen, R.S.Bindra, J.H.Woo, O.Arnaout, E.Gerstner, P.J.Zhang, 
B.Rosen, L.Yang, R.Y.Huang, J.Kalpathy-Cramer. “Residual Convolutional Neural Network for 
Determination of IDH Status in Low-and High-grade Gliomas from MR Imaging” Clin Cancer Res. 
2017 Nov 22. pii: clincanres.2236.2017. doi: 10.1158/1078-0432.CCR-17-2236 
• B.M.Ellingson. “Radiogenomics and imaging phenotypes in glioblastoma: novel observations and 
correlation with molecular characteristics” Curr Neurol Neurosci Rep. 2015 Jan;15(1):506. DOI: 
10.1007/s11910-014-0506-0 
• O. Gevaert, L.A. Mitchell, A.S. Achrol, J. Xu, S. Echegaray, G.K. Steinberg, S.H. Cheshier, S. Napel, 
G. Zaharchuk, S.K. Plevritis. “Glioblastoma multiforme: exploratory radiogenomic analysis by 
using quantitative image features” Radiology. 2014 Oct;273(1):168-74. doi: 
10.1148/radiol.14131731. 
• A.Mahajan, A.V.Moiyadi, R.Jalali, E.Sridhar. “Radiogenomics of glioblastoma: a window into its 
imaging and molecular variability” Cancer Imaging. 2015; 15(Suppl 1): P14. DOI: 10.1186/1470-
7330-15-S1-P14 
• S.H.Patel, L.M.Poisson, D.J.Brat, Y.Zhou, L.Cooper, M.Snuderl, C.Thomas, A.M.Franceschi, 
B.Griffith, A.Flanders, J.G.Golfinos, A.S.Chi, R.Jain. “T2-FLAIR Mismatch, an Imaging Biomarker 
for IDH and 1p/19q Status in Lower Grade Gliomas: A TCGA/TCIA Project” Clin Cancer Res. 2017 
Oct 15;23(20):6078-6085. DOI: 10.1158/1078-0432.CCR-17-0560. 
• E.S. Tykocinski, R.A. Grant, G.S.Kapoor, J. Krejza, L.Bohman, T.A.Gocke, S. Chawla, C.H. 
Halpern, J. Lopinto, E.R. Melhem, D.M. O’Rourke. “Use of magnetic perfusion-weighted 
imaging to determine epidermal growth factor receptor variant III expression in glioblastoma” 
Neuro Oncol. 2012 May; 14(5): 613-623. doi:10.1093/neuonc/nos073. 
• B.Zhang, K.Chang, S.Ramkissoon, S.Tanguturi, W.L.Bi, D.A.Reardon, K.L.Ligon, B.M.Alexander, 
P.Y.Wen, R.Y.Huang. “Multimodal MRI features predict isocitrate dehydrogenase genotype in 
high-grade gliomas.” Neuro Oncol. 2017 Jan;19(1):109-117. DOI: 10.1093/neuonc/now121. 
 
 
 
3. If the 289 mutation exerts its effects through MMP-1 mediated invasion, then knockdown of MMP-1 
in EGFR-289-expressing cells should revert the cells back to baseline. This kind of data would elucidate 
and solidify the overall hypothesis of this manuscript. 
 
Reviewer #1 raises a valid point regarding MMP-1 knockdown and its effect on cell invasion.  
Although we have demonstrated the loss of the invasive phenotype in vitro (Figure 5A-D in the 
manuscript), in our revised manuscript we have now included new data indicating shMMP1-
mediated loss of the invasion in vivo as shown below (Figure 5G-H) and text on Page 8 stating 
“Finally, MMP1 knockdown in vivo nullified the invasive phenotype attributed to the EGFRA289V 
mutation (Figure 5G-H).”  
 
Figure 5G-H. Abrogation of invasive phenotype in vivo was obtained with knockdown of MMP1 in both U87 (G) 
and HK281 (H). 
 
 
 
Reviewer #2: This study begins with investigation of 260 IDH1-wt, de novo GBM patients, looking for 
clinicopathologic correlates of EGFR extracellular domain (ECD) mutations. The cohort is typical, with 
38% harboring EGFR amplification and ~10% with ECD point mutations including 6% with A289D/T/V 
mutations (A289-mt). These cases are the focus of analysis of survival as well as MRI radiomic correlative 
features. The main claims are that EGFR missense mutations of A289D/T/V (A289-mt) are associated 
with shorter median OS (6 months vs. 15 months), and increased invasion and higher proliferation based 
on MRI feature analysis. The authors go on to explore potential mechanisms using glioma cell lines 
engineered to express different ECD mutations. Finally, the authors investigate a hypothesis that A289-
mt exposes an epitope targeted by the EGFRvIII-directed mAb 806 by testing the antibody in mice 
bearing glioma cell line orthotopic tumors +/- A289-mt. 
 
The claim of distinct clinicopathologic features for EGFR A289-mt GBMs in patients is foundational to 
this study. As the authors point out, EGFR genotype is particularly heterogeneous within and across 
GBMs. A289 mutation commonly occurs with EGFR amplification and can co-occur with other EGFR 
mutations in the same tumor. The authors have previously shown that intratumoral heterogeneity of 
EGFRvIII mutation can itself be a strong driver of growth and invasion. Therefore one might expect that 
direct effects of A289-mt on growth or invasion would be modulated by other factors in human tumors-- 
hard to pull out of a small sample set of 15 tumors. Although the finding of potential clinicopathologic 
correlates is intriguing, the handling of methods and statistics (particularly false discovery rate) does not 
allow for a clear conclusion. 
 
There are a few specific points relevant to the human tumor analysis: 
 
Whether EGFR amplification or mutation is prognostic becomes an important issue when considering 
clinical trials (including ongoing trials of EGFR inhibition in GBM). If A289-mt tumors were truly more 
deadly, then one might be tempted to direct patients with the mutation to trials early-on in their course 
of treatment. Study design would need to account for the worse prognosis of A289-mt patients in 
survival analysis. The current study finds median OS of 6 months in such patients, suggesting little 
benefit from conventional therapy. It is important to establish whether this is a real effect. 
 
1. Figure 1 shows Kaplan-Meier analysis for 4 GBM subsets defined by specific EGFR alterations. The 
difference in median OS for A289-mt tumors is marginally significant, and is insignificant if correction for 
multiple comparisons is performed. The manuscript does not frame a specific hypothesis related to 
A289-mt at the outset, so I assume that the selection of this genotype after prognostic analysis of all 
ECD mutations requires p-value correction. This should be addressed in the text. Claims that the data 
demonstrate a prognostic effect or clinical significance of A289-mt should be restated in softer 
language. 
  
Because Reviewer #2’s Comment 2 refers back to Comment 1, we have responded to Reviewer #2’s 
Comments 1 and 2 together, following Comment 2. 
 
2. The authors reference TCGA data for support, but fail to show a simple validation of a prognostic 
effect of A289-mt status. This would render moot the issue of p-values for their exploratory analysis in 
their own cohort. A simple comparison survival analysis of TCGA primary GBM cases +/- mutation at 
A289 can be performed on public portals. It should be included in this manuscript. 
 
We agree with Reviewer #2 that demonstration of the survival impact of EGFRA289 mutations in a 
second cohort would strengthen the conclusions and render moot the issue of p-value corrections for 
our initial exploratory analysis. The initial UPenn cohort contained patient tissue samples assayed at 
UPenn through June of 2016. We have interrogated an additional 111 patients who visited UPenn 
between July of 2016 and June of 2017 (not all patients had an operation during this time; some 
came for second opinions and brought tissue blocks from prior surgeries for sequencing). This 
validation cohort demonstrated a similar occurrence rate of EGFRA289D/T/V, at 4%. Median OS for the 
A289D/T/V mutant population was 4 months, compared to 20 months for EGFRA289, p-value=0.009. 
We have also obtained a second validation cohort from the Hôpital Pitié-Salpêtrière, similarly 
demonstrating a negative survival association with expression of EGFRA289D/V, p-value=0.01. We have 
included both cohorts as the French cohort, while from an independent institution, was collected pre-
2009 and the UPenn cohort is more modern, encompassing patients from 2015-2017. As per our 
biostatistician (E.P.W.), these two cohorts sufficiently address the concerns of p-value correction and 
validation raised here. 
The resulting data has now been included in the manuscript as Figure S1B-C (shown here) and 
text on Page 5, stating “The EGFRA289D/T/V negative survival association was validated using two 
independent cohorts. An additional 111 patients from UPenn were evaluated, showing a negative 
survival association with presence of the EGFRA289D/T/V mutation (p=0.001, Figure S1B). A 116 
patient cohort from Hôpital Pitié-Salpêtrière (Idbaih et al., 2009) demonstrated a similar negative 
survival association (p=0.0208, Figure S1C).” 
In our efforts to secure a validation cohort, we evaluated numerous other patient cohorts, both 
nationally and internationally (see table below). We were unable to confirm our EGFRA289D/T/V survival 
association in these additional datasets and we believe there were several significant issues that 
explain these findings. Variables such as surgical approach (e.g. extent of resection), adjuvant 
treatments, and clinical trial availability and accrual all play a role in data discrepancies. We also 
found that several datasets did not provide sufficient clinical annotation to allow comparison. 
Specifically, the TCGA dataset had incomplete pathological data, making it difficult to parse the 
population and obtain a cohort similar to the UPenn group. The Chinese Glioma Gene Atlas (CGGA), 
while clinically annotated, demonstrated a strikingly different median OS, independent of mutational 
status (OS of 11 months, compared to 15 months at UPenn), in addition to having an occurrence rate 
of EGFRA289D/T/V of three times the Penn cohort (15%, compared to 5% at Penn). Washington 
University had a median OS of 21 months, significantly different from the UPenn cohort. MSK-
IMPACT did not differentiate between de novo and recurrent GBMs and had a median OS of 19 
months. Dana Farber had a similar median overall survival to the UPenn group at 15 months and 
sub-group analysis of the Dana Farber data suggested a negative survival association of EGFRA289D/T/V 
missense mutations in the absence of EGFR amplification. However, this was a small sample size 
(AMP n=5, non-AMP n=3) and the results did not reach statistical significance. In addition, Dana 
Farber used different methods to determine amplification than UPenn (CISH, array CGH, or 
Oncopanel capture-based sequencing as opposed to our NGS-based method), which could impact the 
determination threshold for EGFR amplification. Similarly, each examined cohort used a different 
method for determining EGFR mutational status, which could result in variation in detection 
sensitivity. 
The survival curves for all available national and international cohorts considered, independent 
of mutation status, are shown below. The differences in survival between cohorts demonstrates the 
difficulty in performing cross-cohort analyses. Surgical outcomes, standard-of-care therapy, clinical 
trial enrollment, and other variables all factor into patient survival. An additional possibility is that 
the EGFRA289D/T/V mutations are associated with a hidden covariate. Continued investigation, both 
clinically and in the lab, may lead to further insight, but this exploration falls outside the scope of the 
current manuscript.  
 
Cohort Sample size De novo vs recurrent distinction Median OS 
(Months) 
UPenn Discovery 260 Yes 15 
UPenn Validation 111 Yes 20 
TCGA 522 Mixed 14 
CGGA 84 Yes 13 
Washington University 88 Yes 21 
MSK 210 No 19 
Dana Farber 204 Yes 15 
GGN 183 Yes 16 
Hôpital Pitié-Salpêtrière 116 Yes 14 
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Kaplan-Meier survival curve for overall survival of all cohorts considered. 
 
3. The methodology for selecting the 17 Quantitative Imaging Phenomic (QIP) features is not adequately 
described. 
 
We appreciate the reviewer’s comment on not adequately describing the methodological details of 
the multivariate feature selection approach we followed. In our attempt to clarify how the pruning 
was conducted, we have now elaborated on the selection in the Materials section of the manuscript 
(page 30). We highlight that the feature selection was based off of statistically significant (p<0.05) 
features. Following the suggestion of the editor, we did not include comprehensive mathematical 
formulation of the method we used. However, it can be found in Gaonkar and Davatzikos, 2013, as 
referenced in our paper. 
 
3.1: The first step appears to be extraction of features distinguishing 3 separate ECD mutation classes 
from EGFR-WT. How is the latter set defined? Does EGFR-WT include EGFRvIII? If testing A289-mt, is 
EGFR-WT defined as wildtype at the 289 residue? 
 
Considering this comment in addition to comment 4.2, we realize that the definition of WT EGFR for 
the image analyses was not clear. To avoid any potential misunderstanding or confusion, we have 
now explicitly defined in the Methods section (page 30) that WT EGFR “described only those tumors 
that had confirmed wild-type EGFR at normal expression levels, thereby excluding EGFRvIII, 
amplification, and mutations at A289, R108, and G598 residues.” 
 
3.2: Table S3 lists 17 QIP feature comparisons selected from the preceding analysis. If I understand 
correctly, the table shows only 12 unique QIP features (some are listed twice). 
 
We understand the confusion caused by Table S3. To further clarify why there are some duplicate 
textual descriptions shown in the column describing the QIP “feature observation”, we have now 
expanded the caption of Table S3 to state that “The described feature observations are the ones 
denoted as statistically significant (p>0.05), based on the applied multivariate approach for feature 
selection (Gaonkar and Davatzikos, 2013) and after selection based on radiographic interpretation. 
Furthermore, this table denotes the tumor sub-regions in which each of these feature observations 
were captured, as well as the pairs of EGFR variants that these features were found as statistically 
significant.” 
 
3.3: Table S3: The first feature in the table is presented as distinguishing R108-mt vs. A289-mt. Were 
such ECD vs. ECD discriminations part of the preceding analysis? If so, then it seems that almost no 
features distinguish A289-mt from other ECD mutations. This would not be surprising given the small 
numbers of ECD-mutant cases. 
 
To address the reviewer’s comment, we have now clarified in the Methods section (page 32) that we 
have also “analytically estimated the statistical significance of all extracted radiomic features 
distinguishing the EGFR missense mutants from WT EGFR, as well as between the EGFR mutants”. 
Furthermore, we have now expanded Table S2, which previously included only the statistically 
significant QIP features distinguishing the EGFR mutations from the WT EGFR, to include the 
statistically significant QIP features that distinguish between the ECD mutations assessed in our 
study. Table S3 focused on the features that were radiographically interpretable while Table S2 
focused on features that were statistically significant. 
 
3.4: False discovery rate must be considerable for this exercise, given thousands of QIP features. There is 
no discussion of this, nor of p-value correction (whether performed or not). 
 
We appreciate Reviewer #2’s comment regarding FDR analysis (p-value correction) for our imaging 
component. To address and clarify this concern, we have now added appropriate text in the 
manuscript (Methods, on page 30): 
1. Indeed, we used the p-values assigned by this multivariate method to reduce the QIP features to 
a smaller number (from 2,104) by selecting the ones with the most discriminative power, while 
considering all features jointly. However, statistical significance is not relevant to the scope of 
this imaging analysis, since the latter was used to generate hypotheses that were then tested 
both in silico and in animal models. Even if the outcome findings of the imaging analysis were 
considered to be just trends, the conclusions of this study, after their evaluation in silico and in 
vivo, remained unchanged. 
2. Furthermore, traditional correction methods used for correcting for multiple comparisons (e.g. 
false discovery rate, and/or Bonferroni correction) were designed for multiple independent 
univariate tests. However, in the method we used, the significance of a feature is not calculated 
through univariate tests that use each feature independently. In contrast, the method we used 
for feature selection considers all features together and finds the optimally discriminative 
combination of all features jointly by a multivariate classifier (Gaonkar and Davatzikos, 2013). 
Specifically, the p-value for a feature indicates the significance of the weight assigned to this 
specific feature by the multivariate classifier. Accordingly, in the permutation tests the weights of 
each feature depend on the weights of all other features. Due to this dependence structure, 
application of traditional correction methods (that assume for feature independence) to p-values 
obtained from the method we applied cannot be considered appropriate. Please see a more 
technical discussion of this issue in (Gaonkar and Davatzikos, 2013) Sec 6.2. 
 
4. Figure 2 B-E and the corresponding Results were confusing and the interpretation possibly misleading. 
4.1: Some of the features shown are from Table S3 but others (T2, rCBV) are not. How are these features 
being chosen? 
 
The features discussed in our manuscript were chosen based on their radiographic interpretability. In 
an effort to be inclusive, we have now expanded Table S2 to a comprehensive list of all statistically 
significant feature observations. We have also included the features that were discussed throughout 
the manuscript based on their interpretability, but not reaching statistical significance, together with 
their corresponding p-value. Finally, we have also clarified in our discussion (page 11) that “Although 
some of the features discussed here and shown in Figure 2B-E were not found to be statistically 
significant, they were still chosen to be included in our analysis and discussion as their radiographic 
interpretability was supportive of the overall evaluated radiographic phenotype of the EGFRA289D/T/V 
mutants.” 
 
4.2: It is unclear how the set of EGFR-wt is defined. Does EGFR-wt include EGFR-amplified or vIII-
expressing tumors?  
 
Please refer to our response for comment 3.1. 
 
Other studies have identified radiomic features distinguishing proneural vs. mesenchymal tumors. Some 
of the differences between A289-mt and EGFR-wt shown may in fact reflect differences between EGFR-
driven tumors vs. non-EGFR-driven (including most proneural and mesenchymal tumors, by TCGA 
classification). In order to better distinguish features specific to A289-mt genotype, it would be better to 
show radiomic features compared across A289-mt vs. EGFR-amplified/A289-wt vs. non-EGFR-amplified. 
 
Reviewer #2 makes a valid point concerning the co-occurrence of the EGFRA289D/T/V mutations with 
EGFR amplification. To address the possible confounder, we have now analyzed an additional group 
of only EGFR-amplified patients, where we compared the imaging features across 3 separate groups: 
EGFRA289D/T/V mutants vs non-mutant/EGFR amplified vs non-mutant/EGFR non-amplified (i.e. WT 
EGFR). The results, shown below and included in Figure S3C-D, confirm the feature relationships 
observed were due to the presence of the EGFR missense mutation and not amplification. FA 
homogeneity did not show significance between the mutant and amplified populations; the question 
of the major driving factor for that finding is now the subject of additional work in our group. 
Additional text has been added on Page 6 stating “Comparison of EGFRA289D/T/V mutants to WT 
EGFR and EGFR-amplified cases confirmed the association of the imaging features with the 
A289D/T/V mutation, with the exception of FA homogeneity in the ED (Figure S3C, Table X). 
Consistently, the ED was previously reported as having a unifying MRI signature across various EGFR 
pathway activating alterations (including EGFRvIII, EGFR-amplification, EGFRA289D/T/V, 
EGFRR108K, EGFRG598V) in GBM, compared to WT EGFR (Bakas et al., 2017c)” 
 
 
4.3: The author's interpretation of the biology underpinning radiomic feature differences is speculative, 
and more appropriate for the discussion section. From the observation of decreased T1 signal and 
increased contrast enhancement in A289-mt tumors, it does not follow that these tumors have 
increased neovascularization or proliferation. RCBV is not significantly different between A289-mt and 
EGFR-wt tumors. I could not follow the argument for inferring increased tumor invasion from the select 
imaging parameters shown. 
 
We appreciate the reviewer’s comment that the Results section involved some speculative 
statements, and some parts would be more appropriate for the Discussion section. We have 
removed all speculative text from the Results and moved it to the Discussion. In regards to the 
increased neovascularization hypothesis, increased contrast enhancement could reflect 
neovascularization, which in turn could reflect increased proliferation, per evaluation by our board-
certified Neuroradiologist (M.B.).  As these outcomes are all suppositional and not conclusive, they 
have been moved to the Discussion, on Pages 10-11.  
 
To further assist in following the argument for inferring increased tumor invasion for the A289-mt 
tumors we have added additional figure panels assessing the morphological characteristics of 
these tumors (Figure S3B and shown under Comment 4.2).  The following text has also been added 
to Page 6: “Additional morphological characteristics, while not demonstrating statistical 
significance, displayed relationships further emphasizing the irregular shape of the 
EGFRA289D/T/V mutant tumors (Figure S3B).“ 
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Summary 
We explored the clinical and pathological impact of EGFR extracellular domain missense 
mutations. Retrospective assessment of 260 de novo glioblastoma (GBM) patients revealed a 
significant reduction in overall survival of patients with EGFR mutations at alanine 289 
(EGFRA289D/T/V). Quantitative multi-parametric MRI analyses indicated increased tumor invasion 
for EGFRA289D/T/V mutants, a finding corroborated in mice bearing intracranial tumors expressing 
EGFRA289V and dependent on ERK-mediated expression of matrix metalloproteinase-1 (MMP1). 
EGFRA289V tumor growth was attenuated with an EGFRvIII conformation-specific antibody based 
on a hypothesized structural convergence. Collectively, the findings of this study indicate a 
highly invasive and prognostic indicator for the EGFRA289V missense mutation in GBM, 
postulating EGFRA289V as a molecular marker for responsiveness to therapy with EGFR-
targeting antibodies. 
Keywords: glioma; glioblastoma; GBM; EGFR; A289D/T/V; survival 
Significance 
Although EGFR mutants have different biological activities, we here identify an extracellular 
convergence that may be exploited through broader EGFR ECD targeting. Importantly, when 
designing clinical trials for EGFR targeted therapies, EGFR ECD missense mutations may give 
valuable insight into responsive patient populations. 
Introduction 
Glioblastoma (GBM) is the most common adult, primary, malignant brain tumor with an 
overall incidence rate of 3.2 per 100,000 in the U.S.(Ostrom et al., 2015). With a median overall 
survival (OS) of 14.6 months following standard-of-care (SOC), patients diagnosed with GBM 
have a strikingly poor prognosis (Stupp et al., 2005). Much insight has been gleaned following 
studies describing the somatic genomic alterations in GBM, with the intended goal of defining 
core biological pathways to facilitate the discovery of actionable targets for diagnostic and 
therapeutic purposes (Brennan et al., 2013; Parsons et al., 2008). The 2016 Central Nervous 
System tumor classification of the World Health Organization incorporated molecular 
parameters into traditionally microscopy-based histological classification (Louis et al., 2016). 
Regardless of classification, GBM remains a poorly-margined, diffusely infiltrating necrotic mass 
that is difficult to treat, in part due to its highly invasive phenotype. 
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Intra-tumoral heterogeneity is a key factor in the poor therapeutic success for GBM. A 
seminal study found that 57% of GBM specimens contain a mutation, rearrangement, splicing 
alteration, and/or amplification of the epidermal growth factor receptor (EGFR). While the most 
common EGFR variant is a deletion from exons 2-7, EGFRvIII, extracellular domain (ECD) 
missense mutations comprise 10-15% of transcripts and often co-occur with focal EGFR 
amplification (Brennan et al., 2013). The contribution of cellular cross-talk between EGFR 
variants to GBM pathogenicity sheds light on the importance of dissecting the GBM tumor into 
its single components, rather than focusing on individual mutations (Inda et al., 2010; Zanca et 
al., 2017). While transforming capacity of several ECD EGFR missense mutants has been 
described, sufficient analysis of their downstream signaling pathways, their phenotypic impact 
on the tumor, clinical impact, and potential to specifically target these mutants has yet to be 
elucidated (Lee et al., 2006). 
Multimodal MRI depicts the tumor core as consisting of enhancing (ET), non-enhancing, 
and necrotic (NET) sub-regions, distinct from the peritumoral edematous/invaded region (ED), 
which in combination with the tumor core describe the complete tumor extent (CTE) (Bakas et 
al., 2016). Boosted GLioma Image SegmenTation and Registration (GLISTRboost) is a 
computer-aided method, utilizing machine-learning algorithms to accurately partition gliomas 
into its various distinct sub-regions in multimodal magnetic resonance imaging (MRI) scans 
(Bakas et al., 2017b). This partitioning enables quantitative feature analysis of precise sub-
regions from which the clinician may gain valuable insight into the rational selection of targeted 
agents. 
Here we show that patients expressing the EGFR missense mutations A289D/T/V share 
shorter median OS compared to patients with EGFR that is wildtype at this locus. GLISTRboost 
imaging analysis and in vivo studies revealed a specific phenotype indicative of increased 
invasion and higher proliferation of tumors expressing an A289 mutation. Mechanistic 
exploration of these phenomena demonstrated increased expression of MMP1, driven through a 
constitutively active EGFR/ERK signaling pathway. Based on the structural convergence of 
EGFR ECD deletion and missense mutations in exposing the 806-epitope (Orellana et al., 
2014), we demonstrate that use of the EGFRvIII-specific monoclonal antibody 806 (mAb806, 
precursor to ABT-414 (Phillips et al., 2016)) in animal models significantly reduced tumor growth 
and extended survival of mice bearing A289-mutated gliomas. This is the first study to indicate 
patient stratification based on the presence of an EGFR ECD missense mutation and suggests 
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that convergence in receptor structural alterations with EGFRvIII can be leveraged 
therapeutically.  
Results 
Demographics of the GBM patient population from the University of Pennsylvania 
(UPenn) resemble The Cancer Genome Atlas (TCGA) data 
To investigate the relationship of EGFR ECD missense mutations with GBM patient OS, 
patient records from UPenn from 2013 through 2016 demonstrating a confirmed diagnosis of 
GBM were included for analysis. Of 411 GBM cases, 260 were IDH1 wildtype, de novo GBMs 
with accompanying next generation sequencing (NGS) data from the UPenn Center for 
Personalized Diagnostics (CPD). Male to female ratio was 1.5:1 with a median age of 61 at the 
time of diagnosis (Table S1). The DNA repair protein O6-methylguanine-DNA methyltransferase 
(MGMT) was methylated in 49% of cases. EGFR amplification was identified in 38% of cases 
and EGFRvIII was found in 25% of cases. The most common missense mutations were ECD 
mutations A289D/T/V, R108G/K, and G598V, found in 6%, 3%, and 2% of cases, respectively 
(Figure 1A). Comparison of the frequency and location of EGFR missense mutations in the 
UPenn cohort with data from TCGA demonstrated significant overlap (Figure 1B). Analysis of 
these missense mutations revealed no significant association with gender, age, or EGFRvIII 
status. However, each was found to co-occur with EGFR amplification (Table 1), while R108G/K 
was found more frequently in patients with MGMT methylation. The majority of patients received 
SOC, including surgical resection, concurrent radiotherapy and temozolomide (TMZ), and 
maintenance TMZ. There were no treatment differences in the missense mutation cohorts. 
EGFRA289D/T/V missense mutations confer a negative survival benefit in GBM patients 
Median OS in the complete cohort was 15 months, with a 2-year survival rate of 21%, 
and a 5-year survival rate of 10% (Figure S1A). The median OS, 2-year survival rate, and 5-
year survival rate of patients with A289D/T/V mutations was 6 months, 12%, and 12%, 
respectively (Figure 1C). Patients containing a wildtype EGFRA289 had a median OS of 15 
months, a 2-year OS rate of 22%, and a 5-year OS rate of 11%, demonstrating a significantly 
shorter median OS for patients harboring the A289D/T/V mutations compared to wildtype at that 
same position (p=0.028). Patients with R108G/K mutations had a median OS, a 2-year survival 
rate, and a 5-year survival rate of 17 months, 19%, and 19%, respectively and patients with 
wildtype EGFRR108 had a median OS of 14 months, a 2-year survival rate of 22%, and a 5-year 
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survival rate of 10%, indicating no significant difference (p=0.77, Figure 1D). Finally, patients 
with a G598V mutation had a median OS, a 2-year survival rate, and a 5-year survival rate of 17 
months, 33%, and 33% respectively and patients with wildtype EGFRG598 had a median OS of 
15 months, a 2-year survival rate of 21%, and a 5-year survival rate of 10%, also indicating no 
significant difference (p=0.54, Figure 1E). The discovered EGFRA289D/T/V negative survival 
association was validated using two independent cohorts. An additional 111 patients from 
UPenn were evaluated, showing a negative survival association with presence of the 
EGFRA289D/T/V mutation (p=0.001, Figure S1B). 116 patients from Hôpital Pitié-Salpêtrière 
(Idbaih et al., 2009) demonstrated a similar negative survival association (p=0.0208, Figure 
S1C).  
 Given the association of missense mutation with EGFR amplification, we looked at the 
survival characteristics of patients with amplified EGFR versus those with WT EGFR (Figure 
1F). The median OS for amplified patients was 16 months, compared to 14 months for non-
amplified patients and the 2-year and 5-year survival rates were 17% and 5% for the amplified 
EGFR population compared to 25% and 14% for the WT EGFR population, indicating no 
significant difference between these two populations (p=0.72). 
 As EGFRR108G/K and MGMT methylation were associated, we looked at the survival 
characteristics of MGMT methylated versus unmethylated patients (Figure S1D). As expected, 
the median OS of patients with MGMT methylation was significantly longer than patients without 
MGMT methylation, at 24 months versus 15 months, respectively, and the 2-year and 5-year 
survival rates for MGMT methylated versus MGMT unmethylated were 50% and 18% versus 
14% and 12%, respectively. Collectively, the patient survival data from the UPenn cohort 
revealed a novel oncogenic driving force behind the EGFRA289DT/V mutants, which is distinct from 
EGFR amplification and MGMT methylation status. 
Patient specific MRI signatures of EGFR missense mutants suggest an invasive and 
proliferative phenotype in GBM 
The initial comprehensive set of 2,104 Quantitative Imaging Phenomic (QIP) features 
was pruned into 299 statistically significant (p<0.05) features (Table S2) using a multivariate 
classification framework (Gaonkar and Davatzikos, 2013). QIP features synergistically 
represented altered imaging signals to formulate a descriptive signature of each EGFR variant 
(Figure 2A, S2). Grouped together, comparison of WT EGFR with the missense mutants 
revealed relatively few features that demonstrated statistical significance (Figure S3A, Table 
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S2). However, when we looked at the individual component, each mutation had a unique set of 
features associated with it, rather than a unifying radiophenotype (Table S2). While EGFRR108G/K 
and EGFRG598V did have unique features, the overall picture presented by the EGFRA289D/T/V 
mutations highlighted possible biological mechanisms that could result in the poor patient OS 
associated with this mutation; thus, we focused our attention on this specific mutant. 
The relative contrast enhancement (rCE) in the ET tissue, defined as the subtraction of 
the native T1-weighted signal (T1) from the post-contrast (gadolinium) T1 signal (T1Gd), 
demonstrated a higher value in the presence of an EGFRA289D/T/V mutation (Figure 2B). To 
investigate the cause of the increased rCE, we assessed the mean value of the T1 signal in the 
ET. This revealed lower values in the presence of the EGFRA289D/T/V mutation, indicating that the 
higher contrast value was not solely due to the presence of contrast, but also a lower native T1 
signal. Examining the T2 value in the ET, we found that EGFRA289D/T/V mutant tumors had higher 
values. When combined with the T1 and rCE data, these values supported a radiographic 
phenotype of higher water content in the tissue. To elucidate a possible cause for this, we 
examined relative cerebral blood volume (rCBV) and peak height (PH) in the ET (Figure 2C), 
where both parameters showed higher values in the EGFRA289D/T/V population. 
When looking at the CTE, we found the ratio of major to minor axes associated with 
EGFRA289D/T/V significantly different (Figure 2D). The major axis was defined as the largest 2D 
distance and the minor axis is perpendicular to the major axis. Additional morphological 
characteristics, while not demonstrating statistical significance, displayed relationships further 
emphasizing the more irregular shape of the EGFRA289D/T/V mutant tumors compared to that of 
the WT EGFR (Figure S3B). Furthermore, the quantitative assessment of the ED region 
revealed decreased homogeneity of fractional anisotropy (FA) for the EGFRA289D/T/V mutation 
(Figure 2E), indicating decreased tissue organization, and increased rCE signal. Comparison of 
EGFRA289D/T/V mutants to WT EGFR and EGFR-amplified cases confirmed the association of the 
imaging features with the A289D/T/V mutation, with the exception of FA homogeneity in the ED 
(Figure S3C-D). The ED was previously reported as having a unifying MRI signature across 
various EGFR pathway activating alterations (including EGFRvIII, EGFR-amplification, 
EGFRA289D/T/V, EGFRR108K, and EGFRG598V) in GBM, compared to WT EGFR (Bakas et al., 
2017c). 
Mice bearing intracranial EGFRA289V tumors have attenuated survival and an invasive 
phenotype 
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Based on patient imaging analysis, we hypothesized that EGFRA289 missense mutations 
conveyed enhanced tumor growth and invasion distinguishable from amplified WT EGFR 
activity. To test this, we engineered U87 glioma cells and HK281 GBM-spheres to express 
either WT EGFR or EGFRA289V at levels associated with amplified EGFR found in GBM 
(Nishikawa et al., 1994). Corroborating our findings in the GBM patient population, mice bearing 
intracranial tumors harboring the EGFRA289V mutation had a significantly worse survival rate 
compared to those engrafted with WT EGFR-expressing tumors (Figure 3A, 3C). Histological 
examination of these tumors revealed a striking increase in invasive fronts as well as increased 
Ki67 staining (Figure 3B, 3D, S4A-B).  
 Comparison of EGFRA289V with WT EGFR tumors by T2-weighted MRI at Day 14 further 
demonstrated a striking difference between the two conditions (Figure 3E-F), and corroborated 
our radiographic findings in GBM patients. The scans of WT EGFR tumors showed little if any 
disruption of the normal brain; however, the EGFRA289V images demonstrated large, necrotic 
tumors with poorly demarcated borders, suggesting an invasive phenotype. While limited 
modalities of animal imaging do not allow for a quantitative analysis, increased T2 signal 
throughout the EGFRA289V tumors and in the peritumoral region showed a similar pattern to the 
patient data. Follow-up histological examination of the imaged brains revealed highly cellular, 
poorly demarcated, and invasive neoplasms mainly developing unilaterally within the injected 
neuroparenchyma, confirming the invasive edge of the U87 EGFRA289V tumors (Figure S4C-D). 
EGFRA289V missense mutation induces ERK activation and increased MMP1 expression 
The results above indicated an aggressive tumor growth phenotype that was imparted 
by the EGFRA289V mutation in both patients and animal models. To characterize the molecular 
underpinnings of this mutation, we first examined the expression of matrix metalloproteinases 
(MMP) 2 and 9, known to convey enhanced glioma cell invasion (Das et al., 2011; Nakada et 
al., 2003). Surprisingly, we did not find any effect of EGFRA289V on MMP2 or 9 gene expression 
or secretion in U87 cells (Figure S5A-B). Additionally, invasion through gelatinous substrates 
was unaffected by EGFRA289V expression (Figure S5C). Next, we examined a panel of MMPs 
known to be expressed in glioma cells (Hagemann et al., 2012). Here we found a significant 
increase in MMP1 expression in U87 cells expressing EGFRA289V compared to WT EGFR, 
EGFRR108K, and EGFRG598V, which was also induced in HK281 GBM-spheres expressing 
EGFRA289V compared to WT EGFR (Figure S5, 4A, 4G). 
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 The EGFRA289V missense mutation has been shown previously to be constitutively 
activated (Lee et al., 2006). To examine the downstream signaling pathways that may have 
contributed to increased MMP1 expression, we interrogated known signaling effectors by 
immunoblot analysis of U87 glioma cells harboring mutant EGFR variants. Our results confirm 
that the EGFRA289V mutation leads to constitutive EGFR activation (Figure 4B). Furthermore, 
analysis of downstream MAPK, AKT, and STAT3 signaling pathways revealed a striking 
constitutive activation in the signaling molecule p42/44 MAPK (ERK) in cells expressing the 
EGFRA289V mutant. Importantly, when we inhibited this signaling pathway using two different 
MEK inhibitors, U0126 and PD98059, or the tyrosine kinase inhibitors gefitinib and lapatinib, 
there was a significant reduction in MMP1 gene expression (Figure 4C-F). We confirmed this 
EGFRA289V-driven EGFR/ERK/MMP1 signaling pathway in the HK281 GBM-spheres (Figure 4G-
I). 
EGFRA289V constitutive EGFR/ERK/MMP1 signaling results in increased invasion and 
proliferation in vitro 
 To further delineate the effect of EGFRA289V on EGFR/ERK/MMP1 signaling, we used 
modified Boyden Transwells coated with collagen, in the presence or absence of MEK inhibitors 
(Figure S6A-B). Corroborating our in vivo findings, both U87 cells and HK281 GBM-spheres 
expressing the EGFRA289V mutation showed increased invasion compared to their WT 
counterparts. When we blocked the ERK signaling pathway by U0126, we rescued the effect in 
EGFRA289V cells to the level of WT (Figure 5A, 5C). To test the role of MMP1 in this assay, we 
transduced the EGFRA289V-expressing cells with either an shRNA targeting MMP1 or a control 
shRNA (Figures S6C-D), and showed that in both in vitro glioma models, invasion was 
attenuated upon MMP1 knockdown (Figure 5B, D). 
Next, we tested if increased Ki67 staining in vivo was due specifically to the expression 
of EGFRA289V (Figure 3B, 3D) by quantifying BrdU incorporation (Figure S6E). We found that 
EGFRA289V expressing cells had a significantly higher percentage of active proliferation than WT 
cells in both U87 and HK281 models. Treatment with U0126 again reversed the phenotypic 
difference, bringing the proliferation percentage in the EGFRA289V cells to a level comparable to 
the WT EGFR cells (Figure 5E-F). Finally, MMP1 knockdown in vivo nullified the invasive 
phenotype attributed to the EGFRA289V mutation (Figure 5G-H). The results from these 
experiments indicated that the increased invasion and proliferation in EGFRA289V expressing 
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mutant cells was due to a constitutively active EGFR/ERK/MMP1 signaling pathway that can be 
rescued through pharmacological inhibition. 
mAb806 is a potential therapeutic option for patients expressing EGFRA289V 
 The antibody-drug conjugate, ABT-414, that specifically recognizes EGFRvIII and WT 
EGFR when expressed at amplified levels, has shown promise in phase I/II clinical trials for 
GBM patients (Gan et al., 2017; Phillips et al., 2016; Reardon et al., 2017). Prior work has 
shown that mAb806 detects a convergent structural feature related to constitutive activation, 
which is shared by heterogeneous EGFR ECD missense mutations, including EGFRA289V 
(Orellana et al., 2014). To examine the potential efficacy of this therapy for patients expressing 
EGFRA289V, we used flow cytometry to confirm the ability of mAb806 to bind EGFRA289V. We 
found mAb806 bound EGFRA289V significantly better than WT EGFR in both U87 and HK281 
models (Figure 6A-B). We next assessed the efficacy of this drug in vivo using subcutaneous 
and intracranial tumor models. To directly test the ability for mAb806 to reduce tumor growth, 
we engrafted mice subcutaneously with U87 glioma cells expressing WT EGFR, EGFRA289V, or 
EGFRvIII and treated mice with either mAb806 or vehicle. Using a low dose of mAb806 (0.1 
mg/mouse) previously shown to have no effect on WT EGFR expressing cells (Mishima et al., 
2001), we verified these results and also show that there is a similar reduction in tumor growth 
when cells express the EGFRA289V mutation compared to the EGFRvIII deletion mutation (Figure 
6C). 
To test if mAb806 recognition of the EGFRA289V mutation would lead to an increase in 
survival, fluorescently labeled U87 cells were engrafted orthotopically in mice, followed by 
treatment with mAb806 or vehicle and fluorescence molecular tomography imaging (FMT). By 
Day 16, FMT imaging indicated a strong reduction in fluorescence intensity in mAb806 treated 
mice bearing tumors expressing EGFRA289V or EGFRvIII, and this difference further intensified 
over the next week (Figure 6F-G, Day 23). It became clear that the difference in FMT intensity, 
a direct indicator of intracranial tumor volume, correlated with survival (Figure 6H). In addition to 
the EGFRvIII model (p=0.0025), mAb806 therapy significantly enhanced animal survival in mice 
bearing EGFRA289V expressing tumors (p=0.0015), with only a mild effect on mice bearing WT 
EGFR expressing tumors (p=0.06). This result was reproduced in in the HK281 GBM-sphere 
model (Figure 6I: WT EGFR expressing tumors p=0.085, EGFRA289V expressing tumors 
p=0.0048, Figure S7C-D). This is the first study showing that an EGFRvIII-directed therapy is 
beneficial to tumors expressing a different EGFR ECD mutation, due to a structural convergent 
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feature first predicted in silico (Orellana et al, 2014). These results suggest that the EGFRA289V 
mutation, in addition to EGFRvIII, may be considered a good prognostic indicator for patients 
undergoing clinical trials with ABT-414. Collectively, this data justifies the further development of 
EGFR ECD targeting reagents for GBM therapy. 
Discussion 
In this study, we have demonstrated that the UPenn cohort of GBM patient specimens 
matches the literature, in terms of demographics, survival, and EGFR mutational frequency and 
location (Cerami et al., 2012; Stupp et al., 2005). Median OS of patients with GBM following 
SOC treatment, in the literature, is 14.8 months, closely matching the 15 months OS of our 
cohort (Stupp et al., 2005). Median age at diagnosis and male: female ratio also closely 
matched the population data (Dubrow and Darefsky, 2011), as did MGMT promoter methylation 
status, the only prognostic biomarker in GBM (Hegi et al., 2005). EGFRvIII expression and 
EGFR amplification were lower in the UPenn cohort than in the literature (Heimberger et al., 
2005), potentially because our assessment of EGFR amplification was based on the read depth 
from NGS, compared to fluorescent in situ hybridization (FISH), which is often used in the 
literature. While NGS offers multiple advantages over FISH, including high-throughput nature 
and objective quantification, it also averages the reads across the tumor sample. In contrast, 
FISH assesses individual cells, avoiding the possibility of sample dilution via non-neoplastic 
sources such as stroma and microglia. 
A deeper look at EGFR alterations revealed a trio of ECD missense mutations second to 
EGFRvIII in frequency. EGFRR108G/K, EGFRA289D/T/V, and EGFRG598V are the most common 
missense mutations in both the UPenn cohort and the TCGA population (Cerami et al., 2012). 
Prior work has demonstrated that these missense mutations have tumorigenic potential (Lee et 
al., 2006). In addition, structural work on these mutations has pointed towards increased ligand 
affinity (Bessman et al., 2014). Thus, the overall impact of these mutations could be anticipated 
to be over-activation of EGFR-driven pathways, leading to increased cell proliferation and 
invasion (Talasila et al., 2013; Xing et al., 2013). Additionally, we have shown that these 
mutations share the exposure of a conformational epitope for the antibody mAb806, which is 
related to ligand-independent activation, increased oncogenicity, and predictive of their 
response to kinase inhibitors (Orellana et al., 2014). 
Turning towards the clinical outcomes from our patient cohort, EGFRA289D/T/V was 
associated with a worse OS when compared to WT EGFR at the A289 position. In contrast, 
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EGFRG598V was not associated with survival and EGFRR108G/K presented a complex picture: 
while the OS trend was neither positive nor negative, EGFRR108G/K mutations were shown to 
occur in the presence of MGMT methylation. As MGMT methylation is known to confer 
sensitivity to TMZ treatment and result in increased OS (Stupp et al., 2005), the true survival 
impact of the EGFRR108G/K mutation could not be elucidated. 
There is increasing evidence demonstrating the validity of advanced computational 
analysis of QIP features that has shown promise in predicting clinical outcome and molecular 
characteristics (Aerts, 2016; Bakas et al., 2017a; Bakas et al., 2017c; Ellingson et al., 2017; 
Gevaert et al., 2017; Gill et al., 2014; Gutman et al., 2013; Itakura et al., 2015; Macyszyn et al., 
2016; Zhang et al., 2017). In this study, examination of QIP features associated with the EGFR 
missense mutations helped to generate hypotheses for the negative survival impact of 
EGFRA289D/T/V. The water content picture presented in the ET could have been due to either 
increased “leakiness” of existing vessels or increased total blood content as a result of 
increased neovascularization (Aronen et al., 1994). Together with the relationship of PH values 
and rCBV values between EGFRA289D/T/V and WT EGFR, this presents a picture of increased 
proliferation in the ET, and we hypothesized that there was increased total neovascularization. 
The morphological characteristics of the CTE presented a picture of a highly invasive tumor, 
penetrating further from the tumor in an asymmetrical pattern. The ED, considered a mix of 
tumor and normal brain, showed a loss of normal tissue structure accompanied by 
neovascularization at a level indiscernible to the naked eye, as supported by the decreased 
homogeneity in the FA signal. A shifting of the composition towards tumor cells, due to 
increased invasion, would result in a more chaotic picture as the existing brain architecture is 
disrupted by the tumor cells. Tumor cells would also stimulate neovascularization, leading to the 
increased gadolinium presence (i.e., increased rCE) we discovered in the EGFRA289D/T/V 
mutants. Taken together, the major: minor axes ratio, the FA, and the rCE signals suggest 
increased invasion in the peritumoral ED region of the EGFRA289D/T/V mutant tumors. Although 
some of the features discussed here and shown in Figure 2B-E were not statistically significant, 
they were included in our analysis and discussion as they supported the overall evaluated 
radiographic phenotype of the EGFRA289D/T/V mutants. 
While imaging characteristics can suggest underlying biological processes, verification 
using animal studies is more conclusive. U87 often displays bulky tumors with little presentation 
of invasion in orthotopic implantations (Miura et al., 2010). The invasive picture presented by the 
EGFRA289V mutation represents a significant alteration to both the baseline of U87 and U87 
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expressing WT EGFR. Importantly, we recapitulated this result in the patient-derived HK281 
GBM-sphere model, indicating invasion is an attribute of the EGFRA289V mutant in a more 
pathologically-appropriate model. 
EGFR-mediated signaling acts through two main pathways, Ras/Rak/ERK and 
PIK3CA/Akt, resulting in increased nuclear transcription of genes involved in cellular 
proliferation and tumor invasion. To explore the mechanism behind the in vivo phenotypes we 
found, we examined the activation statuses of these two pathways and performed inhibition 
studies. In both U87 cells and HK281 GBM-spheres, EGFRA289V expression resulted in 
constitutive phosphorylation of EGFR, as seen previously (Lee et al., 2006). Further analyses 
revealed that A289V-mediated EGFR activation resulted in constitutive cellular signaling 
through phosphorylated ERK, ultimately enhancing gene expression of MMP1. Although the 
EGFRA289V ECD missense mutant does respond to EGF (Figure 4B), it does so weakly in 
comparison to wild type or the missense mutants EGFRR108K and EGFRG598V. Interestingly, while 
WT EGFR signals mainly through the STAT3 and MAPK pathways, EGFRvIII preferentially acts 
through the PI3K/AKT pathway (Thorne et al., 2016); EGFRA289V acting primarily through the 
MAPK pathway thus indicates a divergence in oncogenic signaling activation between EGFR 
ECD missense and deletion mutants. 
A role for MMPs in cancer progression and invasion has been widely characterized. 
Specifically, MMP2 and MMP9 have been extensively implicated in GBM progression. It has 
been shown that while MMP1 is not typically expressed in the normal brain, it is elevated in 
gliomas, correlating with tumor grade and survival (Stojic et al., 2008). Here, we reveal a novel 
link between the EGFR ECD missense mutant A289V and MMP1 expression, which results in a 
pro-invasive phenotype. A previous study showed that MMP1 is induced by EGF stimulation in 
glioma cells (Anand et al., 2011), indicating the likelihood of an exacerbated effect of the 
EGFRA289V-mediated invasive phenotype following stimulation. Interestingly, this study also 
indicated EGFR/MAPK signaling for its effect, and therefore it is likely that EGFRA289V would 
mediate its pro-invasive phenotype through this pathway regardless of ligand stimulation. 
Directly targeting MMPs in cancer has proven to be a challenge due to structural 
homology between members of the MMP family and a bilateral role in many cancers (Levin et 
al., 2017). To date, there have been few clinical trials testing MMP inhibitors for GBM. Most 
notably, a Phase II trial combining the broad spectrum MMP inhibitor marimastat with TMZ 
resulted in a PFS at 6 months that significantly exceeded the literature target. However, a 
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separate randomized, double-blind, placebo-controlled trial indicated that the inhibitor on its own 
had no effect on patient survival (Groves et al., 2002; Levin et al., 2006) and further studies 
examining MMP inhibitors for GBM were not conducted. 
Along these lines, a significant contributor to the overwhelmingly poor outcome for GBM 
patients is the relative dearth of active treatments. There are four FDA-approved therapies for 
GBM: TMZ, carmustine implants, bevacizumab, and NovoTTF-100A (Brem et al., 1995; 
Friedman et al., 2009; Stupp et al., 2005; Stupp et al., 2012). Novel therapies are needed to 
improve patient outcomes. Following promising results indicating safety, efficacy studies are 
currently underway for ABT-414, which specifically targets tumor cells expressing aberrant 
EGFR (Reardon et al., 2016). Here we examined the prospects of using ABT-414 against GBMs 
containing the EGFRA289V missense mutant by assessing the efficacy of its non-conjugated 
precursor, mAb806, in subcutaneous and orthotopic animal models. We found that mAb806 
therapy significantly reduced tumor burden and prolonged animal survival in mice bearing 
EGFRA289V positive tumors to a similar degree as to what has been previously published in mice 
bearing EGFRvIII positive tumors (Mishima et al., 2001). Significantly, our data demonstrates 
that ECD mutant structural convergence (Orellana et al., 2014) can be exploited by EGFR-
targeted therapies, and indicates that mAb806 is a viable therapeutic option for tumors 
expressing EGFR mutations other than EGFRvIII. Our study indicates that when deciding 
measurement outcomes for clinical trials with EGFR-targeted therapies, we should not ignore 
the smaller EGFR ECD missense mutation populations, as they may provide valuable insight for 
patient stratification. Importantly, with a baseline poor OS in the EGFRA289D/T/V mutation 
population, survival benefits in this population may be overshadowed by a lack of significant 
survival improvement in the WT EGFR cohort. 
We have demonstrated the clinical significance of the EGFRA289D/T/V missense mutations 
in the context of IDH1 wildtype, de novo GBMs. This negative survival impact was reinforced by 
quantitative imaging analysis suggesting hyperproliferation and increased invasion in patients. 
Decreased OS, increased proliferation, and increased invasion were demonstrated using 
modified cell lines in vivo. Mechanistic exploration revealed increased MMP1 expression driven 
by ERK activation leading to both the increased proliferation and invasion. Finally, the tumor 
driver status of EGFRA289V was demonstrated by in vivo targeting via mAb806, increasing animal 
survival and inhibiting tumor growth. These results serve to highlight the complexity of the 
EGFR signaling cascade and pathway nuances of ECD mutations in the context of cancer. 
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Figure Legends 
Figure 1. EGFRA289D/T/V missense mutations are associated with inferior survival in GBM. (A-B) 
2D representation of EGFR protein with functional domains indicated by colored segments in 
the (A) UPenn cohort and (B) TCGA cohort. The location of mutated amino acids is indicated by 
a bar with a green circle. The height of the bar shows the number of patients in each cohort with 
the specific mutation. Missense mutations at EGFRA289 are the most frequent event in both 
cohorts. (C-F) KM survival curves for the UPenn cohort, comparing (C) EGFRA289D/T/V to 
EGFRA289, (D) EGFRR108G/K to EGFRR108, (E) EGFRG598V to EGFRG598, and (F) EGFR amplified to 
non-amplified. See also Figure S1. 
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Figure 2. MRI signatures of EGFR missense mutants suggest an invasive and proliferative 
phenotype. (A) Examples of the four basic/structural MRI modalities used to segment all brain 
scans into healthy and tumor labels, along with the major axis, minor axis, and the color legend 
for each label. (B) Selected features found in the ET region presenting a picture of increased 
neovascularization. (C) Features found in the ET region highlighting the invasive nature of the 
EGFRA289D/T/V mutation. (D) Ratio of the major and minor axes of the CTE, highlighting the 
asymmetrical growth pattern of the EGFRA289D/T/V mutants when compared to WT EGFR tumors. 
(E) Features found in the ED region supporting the picture of increased invasion. See also 
Figures S2 and S3. Abbreviations: ET=enhancing tumor; NET=non-enhancing tumor; 
ED=peritumoral edematous/invaded region; CTE=complete tumor extent; WM=white matter; 
GM= gray matter; CSF=cerebrospinal fluid; PH=peak height; rCBV=relative cerebral blood 
volume; FA=fractional anisotropy; rCE=relative contrast enhancement. 
Figure 3. Mice bearing intracranial EGFRA289V tumors have attenuated survival and an invasive 
phenotype. KM survival curves comparing mice implanted with either (A) U87 or (C) HK281 
tumors expressing either WT EGFR or EGFRA289V, n=6 per group, **p<0.01. Representative 
H&E and Ki67 stained sections of (B) U87 and (D) HK281 tumors expressing WT EGFR or 
EGFRA289V harvested at time of sacrifice from mice in A and C. Magnification 40x, insets 100x. 
T2 weighted MRI for (E, left panel) WT EGFR and (F, left panel) EGFRA289V U87 tumors at 20 
days, orthotopically implanted in nude mice. 3D volume segmentation map of (E, right panel) 
WT EGFR and (F, right panel) EGFRA289V mouse brains and tumor. Whole brain is in red and 
tumor is in green. See also Figure S4. 
Figure 4. EGFRA289V missense mutation induces ERK activation and increased MMP1 
expression. (A) RT-PCR analysis of MMP1 gene expression in U87 glioma cells expressing WT 
EGFR, EGFRvIII (V3), EGFRR108K, EGFRA289V, or EGFRG598V. (B, left panel) Western blotting 
analysis of the indicated proteins in serum starved U87 glioma cells expressing WT EGFR, 
EGFRvIII, EGFRR108K, EGFRA289V, or EGFRG598V in the presence or absence of 100ng/ml EGF 
for 10 minutes at 37C. (B, right panel) Densitometric quantification of immunoblot. (C, left panel) 
Western blot analysis of the indicated proteins in U87 glioma cells expressing either WT EGFR 
or EGFRA289V following treatment with gefitinib or lapatinib (4μM, 24h). (C, right panel) 
Densitometric quantification of immunoblot. (D, left panel) Western blot analysis of the indicated 
proteins in U87 glioma cells expressing either WT EGFR or EGFRA289V following treatment with 
U0126 or PD98059 (10μM, 24h). (D, right panel) Densitometric quantification of immunoblot. (E) 
RT-PCR analysis of MMP1 in U87 glioma cells expressing EGFRA289V following treatment with 
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gefitinib or lapatinib (4μM, 24h). (F) RT-PCR analysis of MMP1 in U87 glioma cells expressing 
EGFRA289V following treatment with U0126 or PD98059 (10μM, 24h). (G) RT-PCR analysis of 
MMP1 in HK281 GBM-spheres expressing WT EGFR or EGFRA289V. (H, left panel) Western blot 
analysis of the indicated proteins in HK281 GBM-spheres expressing either WT EGFR or 
EGFRA289V following treatment with gefitinib (4μM), lapatinib (4μM), or U0126 (10μM) for 24h. 
(H, right panel) Densitometric quantification of immunoblot. (I) RT-PCR analysis of MMP1 in 
HK281 GBM-spheres expressing EGFRA289V following treatment with gefitinib (4μM), lapatinib 
(4μM), or U0126 (10μM) for 24h. RT-PCR data shown are fold change gene expression relative 
to GAPDH. Error bars are standard error of the mean of at least three replicates and represent 
at least three independent experiments. See also Figure S5. ns=not significant, *p<0.05, 
**p<0.01, ***p<0.001. 
Figure 5. Constitutive EGFRA289V/ERK/MMP1 signaling results in increased invasion and 
proliferation in vitro. Quantification of invaded (A, B) U87 glioma cells and (C, D) HK281 GBM-
spheres was determined using a modified Boyden Transwell chamber assay coated with 
collagen. A and C, Quantification of WT EGFR and EGFRA289V cell invasion following treatment 
with U0126 (10μM) or control for 24 hours. B and D, Quantification of EGFRA289V cells 
expressing an shMMP1 vector compared to control shRNA. Quantification of % BrdU positive 
U87 (E) or HK281 (F) cells following BrdU incorporation. Cells were treated +/- U0126 (10μM) 
24h prior to BrdU incorporation. Abrogation of invasive phenotype in vivo was obtained with 
knockdown of MMP1 in both U87 (G) and HK281 (H). Error bars are standard error of the mean 
of at least three replicates and represent at least three independent experiments. See also 
Figure S6. ns=not significant, *p<0.05, **p<0.01, ***p<0.001. 
Figure 6. MAb806 as a therapeutic option for patients expressing EGFRA289V. (A, B) FACS 
analysis of (A) U87 glioma cells and (B) HK281 GBM-spheres expressing WT EGFR, EGFRvIII, 
or EGFRA289V. Serum starved cells were incubated with either mAb806 or mAb528 (1μg/1x106 
cells) followed by secondary staining with a FITC-conjugated antibody. Results are shown as 
mAb806 staining normalized to mAb528 (total EGFR). (C) Mice bearing U87 subcutaneous 
tumors expressing either WT EGFR, EGFRv3, or EGFRA289V were treated with PBS 
(100μL/mouse) or mAb806 (0.1mg/100μL/mouse) i.p. 3x/week for 2 weeks once tumors 
reached an average of 100mm3. Mean tumor growth after treatment is shown as a function of 
time. (D) Representative images of IRFP720-expressing tumors as detected by fluorescence 
molecular topography (FMT) in mice. Mice were implanted intracranially with IRFP720 
expressing U87 glioma cells expressing either WT EGFR, EGFRvIII, or EGFRA289V and treated 
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with PBS (100μL) or mAb806 (1mg/100μL/mouse) i.p. every other day from days 0-14. 
Quantification of FMT signal intensity on day 23 post-implantation for each region of interest is 
shown in (E). (F) KM survival curve of mice in (D) and (E). (G) KM survival curve of mice 
bearing HK281 intracranial tumors as described in (D). n=5 for each animal group. See also 
Figure S6. ns=not significant, *p<0.05, **p<0.01. 
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Tables 
Table 1. Demographics of EGFR extracellular domain missense mutations. 
   Mutational Status at ECD Locus  
   Wild Type Mutated Fisher’s Exact Test 
Gender 
A289D/T/V 
Female 95 (92%) 8 (8%) 
0.286 
Male 150 (96%) 7 (4%) 
R108G/K 
Female 98 (95%) 5 (5%) 
0.325 
Male 153 (97%) 4 (3%) 
G598V 
Female 102 (99%) 1 (1%) 
0.408 
Male 152 (97%) 5 (3%) 
Age 
A289D/T/V 
0-29 2 (100%) 0 (0%) 
0.607 
30-49 26 (100%) 0 (0%) 
50-69 147 (94%) 10 (6%) 
70+ 70 (93%) 5 (7%) 
R108G/K 
0-29 2 (100%) 0 (0%) 
0.795 
30-49 26 (100%) 0 (0%) 
50-69 151 (96%) 6 (4%) 
70+ 72 (96%) 3 (4%) 
G598V 
0-29 2 (100%) 0 (0%) 
0.695 
30-49 25 (96%) 1 (4%) 
50-69 153 (97%) 4 (3%) 
70+ 74 (99%) 1 (1%) 
MGMT 
Methylation 
Status 
A289D/T/V 
Unmethylated 118 (97%) 4 (3%) 
0.175 
Methylated 81 (93%) 6 (7%) 
R108G/K 
Unmethylated 120 (98%) 2 (2%) 0.036 
Methylated 80 (92%) 7 (8%) 
G598V 
Unmethylated 118 (97%) 4 (3%) 
0.404 
Methylated 86 (99%) 1 (%) 
EGFR 
Amplification 
A289D/T/V 
Unamplified 161 (99%) 1 (1%) <0.001 
Amplified 84 (86%) 14 (14%) 
R108G/K 
Unamplified 160 (99%) 2 (1%) 0.029 
Amplified 91 (93%) 7 (7%) 
G598V 
Unamplified 161 (99%) 1 (1%) 0.030 
Amplified 93 (95%) 5 (5%) 
EGFRvIII 
Status 
A289D/T/V 
Negative 144 (94%) 10 (6%) 
0.932 
Positive 48 (96 %) 2 (4%) 
R108G/K 
Negative 150 (97%) 4 (3%) 
0.103 
Positive 46 (92%) 4 (8%) 
G598V Negative 149 (97%) 5 (3%) 1.000 
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Positive 49 (98%) 1 (1%) 
Received 
standard-of-
care therapy 
A289D/T/V 
Yes 158 (95%) 9 (5%) 
0.582 
No 78 (93%) 6 (7%) 
R108G/K 
Yes 161 (96%) 6 (4%) 
1.000 
No 81 (96%) 3 (4%) 
G598V 
Yes 163 (98%) 4 (2%) 
1.000 
No 82 (98%) 2 (2%) 
Bolded values represent statistically significant Fisher’s Exact Test p-values. Abbreviations: 
ECD, extracellular domain; MGMT, O6-methylguanine-DNA methyltransferase; EGFR, 
Epidermal Growth Factor Receptor; EGFRvIII, EGFR variant III. 
 
STAR Methods 
Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Frank B. Furnari (ffurnari@ucsd.edu). 
 
Experimental Model and Subject Details 
Patient Cohort 
Patients undergoing surgical resection for a cranial malignancy were identified through 
the UPenn CPD. GBM diagnoses were confirmed via medical records containing 
neuropathological assessment. Exclusion criteria were IDH1 mutation as determined by NGS, 
1p19q co-deletion, recurrent resection, and prior diagnosis of a lower grade glioma. There were 
a total of 260 cases that fit all the criteria. Full patient demographics are presented in Table S1. 
 
Cell Lines 
U87 glioma cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% FBS and 1% penicillin/streptomycin. HK281 GBM-spheres (a kind gift from 
Harley Kornblum, UCLA, (Visnyei et al., 2011)) were cultured in DMEM/F12 medium 
supplemented with 1x B27 (GIBCO/Life Technologies), 1% penicillin/streptomycin, human 
recombinant EGF (20 ng/mL), bFGF (20 ng/mL) and 2 mg/mL heparin (StemCell Technologies). 
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All cells were maintained at 37°C, 5% CO2, and 100% relative humidity for the duration of the 
experiment. Reagents used in this study were obtained from the following sources: Antibodies: 
EGFR (BD Biosciences), pan-phospho-Tyrosine-HRP (R&D Systems), p42/44 MAPK, phospho-
p42/44 MAPK, STAT3, phospho-STAT3 y705, AKT, phospho-AKT s473 (Cell Signaling 
Technology), Ki67 (Santa Cruz Biotechnology), and β-Actin (Sigma). Inhibitors: U0126 and 
PD98059 (LC Laboratories). The monoclonal antibody 806 was produced in the Biological 
Production Facility at the Olivia-Newton John Cancer Research Institute (Melbourne, Australia). 
 
Animals  
All animal experiments were performed in accordance with the IACUC at the University 
of California, San Diego or the University of Pennsylvania. Four to six week old female Athymic 
nu/nu mice were used for the subcutaneous tumor studies and six to eight week old female 
Athymic nu/nu mice were used for the intracranial tumor studies (Charles River Laboratories, 
Frederick, MD; The Jackson Laboratory, Bar Harbor, ME). For subcutaneous studies, mice were 
injected into the rear right flank with 2.5x105 U87 glioma cells expressing WT EGFR, EGFRvIII, 
or EGFRA289V. When tumors reached an average size of 100 mm3 mice were injected 
intraperitoneally with either PBS control or mAb806 antibody (0.1 mg/mouse in 100 μL PBS) 
3x/week, for two weeks. Tumor width (a) and length (b) were obtained using calipers and tumor 
volumes were determined using the formula V = ½ x a2 x b, where b ≤ a. Mice were euthanized 
when tumor volumes exceeded 1,500 mm3. For intracranial studies, mice were anesthetized 
and fixed in a stereotactic apparatus, and a burr hole was drilled at 2 mm right or left lateral to 
bregma. U87 glioma cells or HK281 GBM-spheres expressing WT EGFR, EGFRvIII, or 
EGFRA289V (1 × 105 cells) were implanted at a depth of 3 mm. Every other day, from day 0 – 14, 
mice were injected intraperitoneally with mAb806 or PBS control (1 mg/mouse in 100 μL PBS). 
Animals were observed daily and were euthanized when they showed signs of morbidity. 
 
Method Details 
EGFR Mutational Status 
EGFR mutation status (single nucleotide variants, indels) was obtained from the CPD 
through an NGS assay. Briefly, formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks 
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were selected by a neuropathologist and sent to the CPD for processing. DNA was extracted 
from the tissue following manufacturer’s instructions (Qiagen, Valencia, CA). After extraction, 
DNA quality and concentration were assessed (Agilent, Santa Clara, CA; Life Technologies, 
Waltham, MA). For NGS, between 10 and 200 ng of DNA was used to prepare the library. 
Samples were multiplexed and read on a MiSeq (Illumina, San Diego, CA) with an average read 
depth of 2500x. NGS data was processed through an in-house bioinformatics pipeline, 
identifying variants and amplifications of EGFR by standard methods. 
 
EGFRvIII Expression 
EGFRvIII determination was made by NGS sequencing through the CPD. A total of 204 
of the 260 cases were assessed for EGFRvIII expression. Briefly, using primers designed to 
capture both EGFRvIII and WT EGFR, NGS library preparations were amplified and sequenced 
using MiSeq (Illumina, San Diego, CA). The resulting data was processed through an in-house 
bioinformatics pipeline that quantified EGFRvIII as a fraction of total EGFR. Samples with an 
EGFRvIII fraction greater than 5% were considered to be positive. 
 
MGMT Methylation 
A total of 209 cases were examined for MGMT promoter methylation. The initial 91 
samples were sent out to an outside laboratory (ARUP, Salt Lake City, UT). The remaining 118 
samples were processed at UPenn. Briefly, DNA was extracted from FFPE blocks following 
manufacturer’s instructions (Qiagen, Valencia, CA). Bisulfite conversion was carried out 
according to manufacturer’s instructions (Zymo Research, Irvine, CA) and DNA was then 
amplified using PCR targeting 4 CpG islands in exon 1 of MGMT. The PCR results were then 
pyrosequenced to assess the presence of methylation at each CpG island (Qiagen, Valencia, 
CA). 
 
Magnetic Resonance Imaging Acquisition 
The assessed patients were pre-operatively scanned, as part of the UPenn standard 
care protocol of patients with brain tumors, using an advanced MRI acquisition protocol of 6 
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different modalities, comprising native (T1) and contrast-enhanced (T1Gd) T1-weighted, T2-
weighted (T2), T2 Fluid-Attenuated Inversion Recovery (T2-FLAIR), Diffusion Tensor Imaging 
(DTI), and Dynamic Susceptibility Contrast (DSC) MRI volumes. The GBM patients with 
available advanced MRI brain scans included 13 WT EGFR, 11 EGFR-amplified, 11 
EGFRA289D/T/V, 4 EGFRR108G/K, and 4 EGFRG598V. The protocol was approved by the Institutional 
Review Board at the Hospital of the University of Pennsylvania (HUP), and informed consent 
was obtained from all subjects. No randomization method was used for allocating samples to 
experimental groups. 
All MRI scans were acquired in the axial plane using 3-Tesla Siemens Magnetom Trio A 
Tim clinical MRI systems (Erlangen, Germany), according to the standardized advanced 
acquisition protocol followed at the HUP. MRI specifics are available in Table S4. The contrast 
material used in the scans included in this study was either gadodiamide (Omniscan, GE 
Healthcare, Mickleton, NJ), or gadobenate dimeglumine (MultiHance, Bracco SpA, Milan), and 
administered intravenously (IV). The total dose of contract material was divided into two IV 
injections to help minimize errors due to potential contrast leakage out of intravascular space. 
The initial loading dose described the 25% of the total injected contrast material and the second 
bolus injection the remaining 75%, with a delay of 5-minutes. The exact contrast material 
dosage was dependent on patient weight and given on a relative proportion of 0.3 mL/kg. The 
T2 volumes were acquired prior to any contrast administration. The T2-FLAIR volumes were 
acquired between the initial IV injection and the DSC acquisition. The DSC acquisition was 
performed during the second IV injection of the contrast material. DTI scans (Axial 2D) were 
acquired using a single-shot spin echo planar imaging sequence (Variant: segmented k-
space\spoiled, Options: Partial Fourier-Phase\Fat Saturation), with 95 phase encoding steps. 
Following acquisition at b=0 s/mm2 (repeated 3 times), diffusion weighted images were acquired 
(b=1000 s/mm2) with diffusion gradients applied in 30 directions. 
 
Image Pre-processing 
All acquired volumes were converted from DICOM to NIfTI and oriented to the RAI 
coordinate system convention, as part of the requirements of the segmentation algorithm we 
used (Bakas et al., 2017b). All patient scans were co-registered to a single T1Gd template using 
an affine registration, through the Oxford center for Functional MRI of the Brain (FMRIB) Linear 
Image Registration Tool (FLIRT) (Jenkinson et al., 2002) of the FMRIB Software Library (FSL) 
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(Jenkinson et al., 2012). All brain scans were then skull-stripped using a template library of 216 
MRI brain scans and their corresponding masks. This library was used for target specific 
template selection and subsequent registrations MUlti-atlas Segmentation utilizing Ensembles 
(MUSE) (Doshi et al., 2016). A final step based on region-growing guided by the T2 signal was 
applied to obtain a brain mask that includes the intra-cranial CSF. High frequency intensity 
variations in regions of uniform intensity profile, while preserving the underlying tissue structure 
was then applied using the Smallest Univalue Segment Assimilating Nucleus (SUSAN) 
approach (Jenkinson et al., 2002). Non-uniformities of the image intensity caused by the 
inhomogeneity of the magnetic field during acquisition were removed using a non-parametric, 
non-uniform intensity normalization algorithm (Sled et al., 1998), and the intensity histograms of 
all modalities of all patients were then matched to the corresponding modality of a single 
reference patient. A set of DTI measurements were extracted from the DTI volumes for 
comprehensive analysis, namely the tensor’s fractional anisotropy DTI(FA), radial diffusivity 
DTI(RAD), axial diffusivity DTI(AX), and apparent diffusion coefficient DTI(ADC). Furthermore, 
parametric maps of clinical parameters from the temporal perfusion dynamic volumes (i.e., 
DSC-MRI) were extracted, comprising the relative cerebral blood volume (rCBV), peak height 
(PH) and percentage signal recovery (PSR). Both the DTI and the DSC extracted maps were 
treated as individual image modalities. 
 
Tumor Segmentation 
The method used to segment each tumor into its various histologically distinct sub-regions 
is named GLISTRboost (Bakas et al., 2017b) and it is based on a hybrid generative-
discriminative model. The generative part (Gooya et al., 2012) incorporates a glioma growth 
model (based on a reaction-diffusion-advection model) (Hogea et al., 2007), and follows an 
Expectation-Maximization (EM) framework to segment the brain scans into tumor (i.e., ET, NET 
and ED), as well as healthy tissue labels (i.e., WM, GM, CSF, vessels and cerebellum), and 
register a healthy population probabilistic atlas to glioma patients’ brain scans using the tumor 
growth model to account for mass effects. The discriminative part is based on a gradient 
boosting multi-class classification scheme and used to refine the tumor sub-region labels based 
on information from multiple patients. Lastly, a Bayesian strategy (Bakas et al., 2017d) is 
employed to further refine and finalize the tumor segmentation based on patient-specific 
intensity statistics from the multimodal MRI scans available (Fig. 2A). 
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GLISTRboost is designed to tackle cases with both solitary and multifocal masses of 
complex shapes with heterogeneous texture. It requires manual input of tissue seed-points for 
each segmentation label, to capture the intensity variation and model the intensity distribution 
(i.e., mean and variance) across all modalities. However, the coordinate position of these input 
seed-points is not taken into consideration by the segmentation method, but only the 
corresponding intensity value. Therefore, any potential variation in the coordinates of seed-
points initialized during independent initialization attempts should not affect the output 
segmentation labels, given that the modelled intensity distributions during these attempts are 
the same. In addition to the seed-points for each tissue class, a single seed-point and a radius 
are also required to approximate the bulk volume of each apparent tumor by a spherical 
parametric model, which is then used as a prior to the tumor growth model (Hogea et al., 2007). 
This growth model deforms a healthy population probabilistic atlas into a glioma patient brain 
scan matching the input scan, while approximating the brain tissue deformations occurred due 
to the mass effect of the tumors. A random-walk-based generative model estimates a tumor 
shape prior, initialized by the spherical parametric model. This prior is incorporated in the 
generative part of GLISTRboost via an empirical Bayes model (Gooya et al., 2012) and 
produces a probability map for each tissue label, leading to an integrative non-overlapping 
segmentation label map. This label map is then refined by a voxel-level multi-label classification 
through a gradient boosting ensemble model of decision trees. We trained decision trees of 
maximum depth 3 in a subset of the training data to introduce randomness and using a cross-
validation framework to avoid overfitting. Sampling rate of 0.6 was used, while additional 
randomness was introduced by sampling stochastically a subset (square root of the total 
number of features) of imaging features at each node. The exact features use for training this 
discriminative part of GLISTRboost, consisted of i) intensity, ii) image derivatives, ii) geodesic 
distance transform, iv) texture parameters and the tissue probability maps. The intensity 
parameters comprise the raw intensity voxel value at each MRI modality, as well as their 
differences across all four modalities. The image derivatives are summarized by the Laplacian 
of Gaussians and the image gradient magnitude. These sets of parameters are extracted after 
performing an intensity normalization based on the median intensity of the current cerebrospinal 
fluid segmentation label. The geodesic distance transform was estimated for each voxel from 
the initialized tumor center seed-point (Gaonkar et al., 2015). Texture features were based on a 
gray-level co-occurrence matrix (GLCM) and extracted following discretization of the input 
volumes into 64 gray levels and using a bounding box of 125 voxels (5x5x5) for each voxel of 
each image. The GLCM accounted for intensity values within a radius of 2 voxels and for 26 3D 
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directions to extract the energy, entropy, dissimilarity, homogeneity (i.e., inverse difference 
moment of order 2), and inverse difference moment of order 1. The tumor segmentation labels 
of each patient were then further refined based on individual patient intensities (Bakas et al., 
2017d). First the intensity distributions of the WM, ED, NET and ET were populated, considering 
the corresponding voxels of tissue probability equal to 1. The histograms of the 3 pair-wise 
distributions considered (i.e., ED vs WM in T2-FLAIR, ET vs ED in T1-Gd, and ET vs NET in T1-
Gd) were then normalized. The maximum likelihood estimation was then used to model the 
class-conditional probability densities (Pr(I(vi)|Class) of each class by a distinct Gaussian model 
for each class. The voxels of each class in a close proximity (4 voxels) to the voxels of the 
paired class, were then iteratively evaluated by assessing their intensity I(vi) and comparing the 
Pr(I(vi)|Class1) with Pr(I(vi)|Class2). The voxel vi was then classified into the class with the larger 
conditional probability, which is equivalent to a classification based on Bayes' Theorem with 
equal priors for the two classes, i.e., Pr(Class1) = Pr(Class2) = 0.5. 
 
Extraction of Quantitative Imaging Phenomic Features 
Accurate delineation of the three histologically distinct tumor sub-regions (i.e., ET, NET, 
ED) enabled us to extract QIP features (n=2104), accurately corresponding to each of the sub-
regions. Specifically, these QIP features comprise: 21 volumetric measurements, 11 parameters 
describing the spatial configuration and distribution of the tumor, 1650 radiomic features (150 for 
each modality assessed), 330 histogram-based intensity parameters (30 for each modality), 66 
first order statistics of image intensities (the mean and standard deviation of each sub-region in 
each modality), 21 parameters descriptive of the tumor’s shape, and 5 glioma diffusion 
properties extracted from tumor biophysical models using reaction-diffusion-advection 
equations. 
 
Multivariate Machine Learning Analysis 
An analytic estimation of statistical significance based on multivariate analysis (Gaonkar 
and Davatzikos, 2013) was employed to calculate the relative contribution of each QIP feature 
extracted on distinguishing the EGFR missense mutants from WT EGFR by assigning a 
corresponding p-value. The multivariate approach was based on a support vector machine 
formulation for classification using a linear kernel function. The parameter for the soft margin 
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cost function (c) was optimized on the training data based on a five-fold cross validated grid 
search; c=2α, where αϵ[-5,5]. This parameter controls the influence of each individual support 
vector that involves trading error penalty for stability. This analytic estimation assesses the 
relative individual contribution of each feature, while considering the synergistic interactions with 
other features, and assigns a conservative p-value to each feature for evaluating/quantifying the 
statistical significance of each. Feature selection was conducted by selecting those features 
with a p-value above a certain threshold (p>0.05). Next, we analytically estimated the statistical 
significance (i.e., p-values) of all extracted radiomic features distinguishing the EGFR missense 
mutants from WT EGFR, as well as between the EGFR mutants, based on a multivariate 
classification framework (Gaonkar and Davatzikos, 2013). Note that WT EGFR here described 
only those tumors that had confirmed wildtype EGFR at normal expression levels, thereby 
excluding EGFRvIII, amplification, and mutations at A289, R108, and G598 residues. This 
multivariate analysis enabled us to prune the extensively comprehensive set including 2,104 
QIP features into 299 statistically significant (p<0.05) features (Table S2). Subsequent selection 
of features based on radiographic interpretability, according to a board-certified Neuroradiologist 
(M.B.), further reduced these features to a more manageable set of 17 QIP features (Table S3). 
Typically, p-value corrections for multiple comparisons are considered for assignment of 
statistical significance. However, statistical significance was not relevant to the scope of our 
imaging analysis, since the latter was used to generate hypotheses that were then tested both 
in silico and in vivo. Even if the outcome findings of the imaging analysis were considered 
trends, the conclusions of this study, after their evaluation in silico and in vivo, remained 
unchanged. Furthermore, traditional correction methods used (e.g. false discovery rate, and/or 
Bonferroni correction) were designed for multiple independent univariate tests. In the 
multivariate method we used, the significance of a feature was not calculated through univariate 
tests that use each feature independently. In contrast, our feature selection considered all 
features together and found the optimally discriminative combination of all features jointly by a 
multivariate classifier (Gaonkar and Davatzikos, 2013). Specifically, the p-value for a feature 
indicated the significance of the weight assigned to this specific feature by the multivariate 
classifier. Accordingly, in the permutation tests, the weights of each feature depended on the 
weights of all other features. Considering the assumption of traditional correction methods for 
feature independence did not hold true, their application was not appropriate. 
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Reagents  
Plasmids. For U87 transduction, pLRNL retroviral plasmids containing the full length wild 
type EGFR and the truncated EGFRvIII constructs were previously reported (Zanca et al., 
2017). The EGFR ECD missense mutations were generated from the WT EGFR construct by 
site-directed mutagenesis (Agilent Technology), according to manufacturer’s instructions. 
Primers used were as follows: EGFRA289V forward 5’-caaatacagctttggtgtcacctgcgtgaagaagt-3’ 
and reverse 5’-acttcttcacgcaggtgacaccaaagctgtatttg-3’, EGFRR108K forward 5’-
aaacctgcagatcatcaaaggaaatatgtactac-3’ and reverse 5’-gtagtacatatttcctttgatgatctgcaggttt-3’, 
EGFRG598V forward 5’-caagacctgcccggcagtagtcatgggagaaaaca-3’ and reverse 5’- 
tgttttctcccatgactcatgccgggcaggtcttg-3’. For HK281 transduction, the pLRNL constructs were 
used to subclone WT EGFR and EGFRA289V into the pLV-EF1a-MCS-IRES-Hyg plasmid 
(Biosettia). The near-infrared fluorescent protein IRFP720 cDNA construct was described 
previously (Zanca et al., 2017). The MMP1 Mission shRNA pLKO.1 plasmid was obtained from 
Sigma (clone NM_002421.3-986s21c1). 
 
Retro- and Lentivirus production and transduction 
To produce retrovirus, HEK 293T cells were co-transfected with pLRNL vectors and the 
pCL10A1 packaging construct using Lipofectamine 2000 reagent (Life Sciences). Viral 
supernatants were collected and filtered at 48 and 72 hours following transfection and used to 
infect cells overnight in the presence of 10 μg/mL polybrene. Cells were then selected and 
maintained with neomycin (400 μg/mL). To produce lentivirus, HEK 293T cells were co-
transfected with pLV or pLKO.1 vectors, along with pRev, pMDL, and VSVg packaging 
constructs using Lipofectamine 2000. Supernatants were collected and filtered at 48 and 72 
hours after transfection. Viral supernatant was concentrated by centrifugation at 23,000 x g for 2 
hours at 4°C and used to infect cells overnight in the presence of 10 μg/mL polybrene. Cells 
were selected and maintained with hygromycin (200 μg/mL, pLV-EF1a-MCS-IRES-Hyg), 
puromycin (2ug/ml, shMMP1), or blastocidin (5ug/ml, IRFP720), depending on vector. Gene 
expression was verified by western blot, real time PCR, and FACS analysis.  
 
FACS (Fluorescent-activated Cell Sorter) Sorting and Analysis. 
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For the generation of stable U87 cell lines and HK281 GBM-spheres expressing equal 
levels of EGFR, cells were collected at 1 x 106 cells in 100 μL FACS buffer (PBS + 1% FBS) 
and exposed to 1 μg of the EGFR monoclonal antibody 528, which recognizes WT and mutant 
EGFR, for 1 hour. Cells were then exposed to FITC-conjugated goat anti-mouse IgG antibody 
for 1 hour. Stained cells were analyzed by SH800 Cell Sorter (Sony Biotechnology) and sorted 
to within 10% of the mean FITC intensity of control cells expressing EGFRvIII. Sorted cells were 
cultured and reanalyzed to confirm stability of receptor levels. To measure binding affinity to the 
mAb806 antibody, the cells were processed as above but each cell line was stained separately 
with 1μg of either antibody 528 or mAb806, followed by a secondary staining with a FITC-
conjugated antibody. Mean FITC intensity following mAb806 staining was normalized to the 
corresponding mean FITC intensity for antibody 528.  
 
Western Blotting 
Cells were seeded in 10% FBS overnight to allow for adherence and then serum starved 
for 24 hours and treated with or without EGF at 100 ng/mL for 10 minutes at 37°C. Cell lysates 
were collected on ice with RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% 
Sodium Deoxycholate, 0.1% SDS, 5 mM EDTA) supplemented with protease (Roche) and 
phosphatase (Sigma) inhibitors. Protein concentration was determined using a standard DC 
assay (Bio-Rad) and equal amounts were loaded and separated by SDS-PAGE and then 
transferred to PVDF membranes. The membranes were blocked with buffer containing 5% BSA 
in tris-buffered saline with 0.1% Tween-20 (TTBS) for 1 h and incubated overnight with primary 
antibodies at 4°C. Membranes were washed with TTBS, and then incubated with HRP-
conjugated secondary antibodies (Sigma-Aldrich) and developed with an enhanced 
chemiluminescence detection kit (Pierce). ImageJ software was used to quantify band signal 
intensity normalized to total protein. 
 
FMT Imaging 
For the intracranial in vivo experiments, tumor growth was monitored via fluorescence 
molecular tomography using the FMT 2500 Fluorescence Tomography System (PerkinElmer). 
Signal intensity was calculated based on ROI and analyzed using Perkin Elmer software.  
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Immunohistochemistry  
Formalin-fixed, paraffin-embedded (FFPE) tissue sections were prepared by the 
Histology Core Facility at UCSD Moores Cancer Center. Immunohistochemistry was performed 
according to standard procedures using the Scytek SensiTek HRP (AEC) Staining System. 
Antigen was retrieved by boiling slides in 0.01 M of sodium citrate (pH 6.0) in an oven for 30 
minutes. Sections were incubated with primary antibody at 4°C overnight, followed by incubation 
with biotinylated secondary antibodies at room temperature for 20 min. Nine representative 
images from each immunostained section were taken with a Keyence BZ-X700 microscope and 
analyzed with BZ-X Analyzer Keyence software. 
For pathological examination, the entire head was collected and fixed for approximately 
5 days in 4% PFA at 4 °C. After fixation, brain was removed from the skull and serially sliced 
using the coronal brain matrix system (Zivic Instruments BSMYS001-1). Five slices were 
obtained from each brain using the following anatomical landmarks as references: paraflocculi, 
infundibulum/median eminence, optic chiasm, cranial border of olfactory tubercles. Sliced brains 
were then processed for paraffin embedding (Thermo Scientific Excelsior™ AS Tissue 
Processor and HistoStar™ Embedding Workstation) and serial sagittal sections of 5 µm were 
obtained (Reichert Jung 2030 microtome). Sections were mounted on Superfrost microscope 
slides (Fisherbrand 12-550-14) and stained with hematoxylin and eosin (H&E) using the Gemini 
AS automated slide stainer (Thermo Fisher Scientific). H&E-stained slides were finally 
evaluated by a board certified veterinary pathologist (ER) and representative pictures were 
captured using an Olympus BX53 microscope coupled with an Olympus DP25 camera. 
 
Animal MRI Studies 
All MRI studies were performed in the Small Animal Imaging Facility in the Department 
of Radiology at the University of Pennsylvania, on a 9.4T horizontal bore scanner (Agilent Inc, 
Palo Alto, CA) equipped with a 12 cm ID, 40 gauss/cm gradient tube. Animals were prepared for 
study by induction of general anesthesia using 1-2% inhaled isoflurane through a nose cone. A 
respiration pillow and rectal temperature probe were placed on the animal and attached to a MR 
compatible vital signs monitoring system (Small Animal Instrument Inc, Stonybrook, NY). The 
animals were then mounted in a 20 mm ID quadrature birdcage RF coil (M2M Imaging, 
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Cleveland, OH) and positioned in the magnet. The vital signs monitoring system was equipped 
with a regulated warm air source which was directed over the animal during the study to 
maintain the core body temperature at 37±1°C. Respiration and core body temperature were 
monitored throughout the study and the isoflurane level was adjusted as needed to maintain a 
deep anesthesia. Following optimization of RF transmitter power and generation of scout 
images, a contiguous series of T2-weighted, fast spin echo, axial slices spanning the brain 
(cerebral cortex or cerebellum) was generated with the following parameters: TR = 3800 msec; 
ETL = 8; ESP = min (10.96); kzero = 5; Effective TE = 54.80 msec; averages = 8; dummy scans = 
2; FOV = 20 x 20; matrix = 256 x 256; slice thickness = 0.5 mm; 30 slices total. Images were 
converted to the Meta file format for 3D volumetric analysis using the ITK-SNAP program. The 
total brain volume and volume of the T2 abnormality were determined (Yushkevich et al., 2006). 
The overlay maps were generated using ParaView (Hansen and Johnson, 2005). 
 
Cell Invasion Assay 
In vitro cell invasion was evaluated using a 24-well chemotaxis chamber equipped with a 
polycarbonate filter with 8 μm pores (Costar, Corning, NY). Prior to plating, transwells were 
coated with Pure Col, Bovine Collagen Solution, Type I collagen for 30 minutes at 37°C (1:30 in 
0.1% FBS, DMEM for U87 cells, 1:30 in F12 DMEM for HK281 GBM-spheres). Serum starved 
cells were incubated with the indicated inhibitor for 24 hours prior to plating. Cells were then 
counted and plated in the upper chamber and left to migrate for 6 hours towards 10% FBS, 
DMEM. Following incubation, cells that traversed the membrane were fixed and stained with 
crystal violet and non-migrated cells were removed with a cotton-tipped applicator. Cells were 
quantified by averaging the cell count of 5 different view fields at 20x magnification from at least 
three independent transwells. 
 
BrdU Assay 
For U87 glioma cells, BrdU assessment was carried out as follows: cells were plated on 
coverslips (10,000 cells/well in a 24 well plate), cultured for 7 days, and then incubated in the 
presence of 10 µM BrdU for 4-6 hours. The cells were fixed in 4% PFA (Sigma), stained with 
anti-BrdU antibody (BD), and counterstained with Hoechst 33258 (Sigma). The number of BrdU-
positive cells was scored as a percentage of the total number of cells counterstained with 
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Hoechst 33258. All pictures were captured using Nikon DS-Ri1 microscope. The assay was 
performed in triplicate for all conditions. For HK281 GBM-spheres, cells were plated in 6-well 
dishes (200,000 cells/well), cultured for 24 hours and then incubated in the presence of 10 µM 
BrdU for 6 hours. Cells were washed once with PBS, and 50,000 were plated on coverslips in a 
24-well dish. The plate was centrifuged at 1500rpm for 5 minutes to allow cells to adhere. Cells 
were then fixed with 4% PFA and stained with anti-BrdU antibody as described above. 
 
Real time-PCR  
Cells were harvested with 0.5% trypsin-EDTA, centrifuged for 5 min at 2,000 rpm, and 
cell pellets frozen. Cell pellets were homogenized using a QIAshredder (Qiagen, Valencia, CA) 
and RNA was isolated using an RNeasy Mini Kit (Qiagen, Valencia, CA). Real time continuous 
detection of PCR product was achieved using Sybr Green (Applied Biosystems, Carlsbad, CA). 
GAPDH was used as an internal control with relative quantification being expressed as a ratio of 
the difference in the number of cycles needed for expression of a gene. Primers were designed 
using the Primer3 version 4.0.0. (Table S5). 
 
Zymography   
U87 glioma cells expressing the following EGFR mutations: Parental (non-transduced), 
WT (wild type EGFR over-expressed), V3 (EGFRvIII), V2 (EGFRvII, deletion from exon 14-15), 
R108K, G63R, A289V, A/R (double A289V + R108K), and G598V, were seeded at 1x106 
cells/10cm dish and serum starved for 24 hours. Conditioned media was collected and 
concentrated by centrifugation using Amicon Ultra Centrifugal Filters according to 
manufacturer’s instructions (Ultracel - 10K, Millipore, Billerica, MA). Protein concentration was 
measured and 5ug was loaded onto a 7.5% acrylamide gel containing 0.1% gelatin for SDS-
PAGE. The gel was washed in washing buffer (2.5% Triton X-100, 50mM Tris-HCl pH 7.5, 5mM 
CaCl2, 1uM ZnCl2) for 30 minutes twice, rinsed in incubation buffer (1% Triton X-100, Tris-HCl 
50mM pH 7.5, 5mM CaCl2, 1uM ZnCl2) for 5 minutes and incubated in fresh incubation buffer for 
24 hours at 37C with agitation. Following staining with Coomassie Brilliant Blue for 1 hour and 
decoloration with acetic acid, the gel was imaged using the Chemi-Doc MP Imaging System 
(Bio-Rad).  
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Quantification and Statistical Analysis 
All population analyses were conducted using Stat 14.2 (Stata Corporation, College 
Station, TX). Time to event data were analyzed using Kaplan-Meier methods, and group 
differences were tested using the log-rank test. Other associations among binary or categorical 
variables were analyzed using contingency table methods, and tested using the chi-square 
statistic. Results from experiments are presented as mean values ± standard error of the mean 
(SEM). Statistical analyses were carried out by unpaired Student’s t-test using GraphPad 
Prism® 5.01 software. P values < 0.05 were considered statistically significant. For the animal 
survival analysis, Kaplan–Meier curves were plotted and compared using the log rank test. 
Statistical details can be found in the figure legends. 
 
Data and Software Availability 
The software tool used for skull-stripping (i.e., MUSE (Doshi et al., 2016)) is available in 
www.med.upenn.edu/sbia/muse.html. The software tool used for co-registration (i.e., FLIRT 
(Jenkinson et al., 2002)) is available in: fsl.fmrib.ox.ac.uk. We developed the Cancer Imaging 
Phenomics Toolkit (CaPTk) (Davatzikos et al., 2018) to facilitate clinical translation of complex 
computational algorithms, without requiring computational background (e.g., identification of 
genetic mutation imaging signatures (Bakas et al., 2017a)). Specifically for this study, CaPTk 
was used for 1) initialization of seed-points required by GLISTRboost, 2) image smoothing, as 
well as 3) extracting the quantitative imaging features. The code source, as well as executable 
installers, of CaPTk are available in: www.med.upenn.edu/cbica/captk. Finally, our 
segmentation approach, GLISTRboost (Bakas et al., 2017b), is available for public use through 
CBICA’s Image Processing Portal (IPP - ipp.cbica.upenn.edu), which allows users to perform 
data analysis using integrated algorithms, without any software installation, whilst using CBICA's 
High Performance Computing resources. 
Animal MRIs were converted to the Meta file format for 3D volumetric analysis using the 
ITK-SNAP (www.itksnap.org) program. The total brain volume and volume of the T2 abnormality 
were determined (Yushkevich et al., 2006). The overlay maps were generated using ParaView 
(Hansen and Johnson, 2005). 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
EGFR antibody BD Biosciences 61007 
Pan-phospho-Tyrosine HRP antibody R&D Systems HAM1676 
p42/44 MAPK antibody Cell Signaling Technology 9102 
Phospho-p42/44 MAPK antibody Cell Signaling Technology 9101 
STAT3 antibody Cell Signaling Technology 4904 
Phospho-STAT3 y705 antibody Cell Signaling Technology 9145 
Akt antibody Cell Signaling Technology 9272 
Phospho-Akt s473 Cell Signaling Technology 4060 
Ki67 Santa Cruz Biotechnology Sc-15402 
β-Actin Sigma A 3854 
mAb806 Biological Production 
Facility 
N/A 
BrdU (clone B44) antibody BD Biosciences BDB347580 
Hoechst 33258 Sigma-Aldrich B2883 
Bacterial and Virus Strains  
pLRNL vector Nishikawa et al, 1994 N/A 
pLV-EF1a-MCS-IRES-Hyg Biosettia cDNA-pLV02 
iRFP720 cDNA Shcherbakova et al, 2013 N/A 
Biological Samples   
Chemicals, Peptides, and Recombinant Proteins 
U0126 LC Laboratories U-6770 
U0126 Cell Signaling Technology 9903S 
PD98059 LC Laboratories P-4313 
Critical Commercial Assays 
Deposited Data 
Experimental Models: Cell Lines 
Human: U87 cells ATCC HTB-14 
Human: HK281 GBM-spheres Laboratory of Harley 
Kornblum, UCLA 
N/A 
Experimental Models: Organisms/Strains 
Mouse: Female NCI Ath/Nu Charles River Labs Strain 563 
Mouse: Female J:NU Homozygous The Jackson Laboratory 007850 
Oligonucleotides 
shRNA targeting sequence: shMMP1: 
CCGGGCTAACCTTTGATGCTATAACCT
CGAGGTTATAGCATCAAAGGTTAGCTT
TTTG 
Sigma TRCN0000372933 
shControl: pLKO.1shGFP2 Fenton, et al 2012 N/A 
Primers for Real Time PCR, see Table S2 This paper N/A 
Recombinant DNA 
Software and Algorithms 
MUSE Doshi, J., et al., 2016 www.med.upenn.ed
u/sbia/muse.html 
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FLIRT Jenkinson, M. and S. Smith, 
2001 
fsl.fmrib.ox.ac.uk 
Cancer Imaging Phenomics Toolkit 
(CaPTk) 
Davatzikos, C., et al., (In 
Press) 
www.med.upenn.ed
u/sbia/captk.html 
GLISTRboost Bakas, S., et al., 
GLISTRboost: Combining 
Multimodal MRI 
Segmentation, Registration, 
and Biophysical Tumor 
Growth Modeling with 
Gradient Boosting 
Machines for Glioma 
Segmentation, 2016 
ipp.cbica.upenn.edu 
 
 
http://www.med.upe
nn.edu/sbia/glistrbo
ost.html 
ITK-SNAP Yushkevich, P. A., et al., 
2006 
www.itksnap.org 
ParaView Hansen, C. D., et al., 2005 www.paraview.org 
Other 
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